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ABSTRACT 
 
The cardiac sarco/endoplasmic reticulum calcium ATPase (SERCA) establishes the 
intracellular calcium gradient across the sarcoplasmic reticulum membrane. It has been 
proposed that SERCA forms homo-oligomers that increase the catalytic rate of calcium 
transport. We investigated SERCA oligomerization in rabbit left ventricular myocytes 
using a photoactivatable cross-linker. Western blotting of cross-linked SERCA revealed 
higher molecular weight species consistent with SERCA oligomerization. Fluorescence 
resonance energy transfer (FRET) measurements in cells transiently transfected with 
fluorescently-labeled SERCA2a revealed that SERCA readily forms homo-dimers. These 
dimers formed in the absence or presence of the SERCA regulatory partner, 
phospholamban (PLB) and were unaltered by PLB phosphorylation or changes in calcium 
or ATP. Fluorescence lifetime data are compatible with a model in which PLB interacts 
with a SERCA homo-dimer in a stoichiometry of 1:2. Functional data show that homo-
dimerization of SERCA is an important component of SERCA regulation. Together, these 
results suggest that SERCA forms constitutive homo-dimers in live cells that and dimer 
formation is not modulated by SERCA conformational poise, PLB binding, or PLB 
phosphorylation. 
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CHAPTER ONE 
CARDIAC CALCIUM ATPASE AND THE HEART 
The heart is essential for providing adequate blood flow to meet the demands of 
the body; blood carries oxygen and nutrients to cells and removes carbon dioxide and 
metabolites. Heart failure (HF) arises when the heart is unable to meet the demand for 
oxygen, and is one of the leading causes of morbidity and mortality worldwide 
(Mozaffarian, Benjamin et al. 2016). Clinical treatment of cardiovascular diseases, such 
as HF, continues to be a leading health care cost and places a substantial financial 
burden on healthcare (Mozaffarian, Benjamin et al. 2016). Advances in HF treatment 
from the period 1950-1969 to 1990-1999 reduced one-year mortality rates in men from 
30% to 28% and in women from 28% to 24% (Levy, Kenchaiah et al. 2002). Despite these 
incremental advances, the mortality rates remain unacceptably high with five-year 
mortality greater than 50% (Roger, Weston et al. 2004). There is currently no cure for 
HF. 
Sarco/endoplasmic reticulum calcium ATPase (SERCA) is responsible for 
transporting calcium from the cytoplasm/sarcoplasm to the luminal side of the 
endoplasmic/sarcoplasmic reticulum (ER/SR). It is also the primary means by which 
calcium is removed from the sarcoplasm. This process sequesters calcium in the SR 
lumen. In the heart this process is essential for relaxation of the myocardium, as calcium 
is a necessary signaling molecule that enables actin and myosin interactions to drive 
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muscle contraction (Bers 2002). In addition to altering relaxation of the heart, SERCA 
also affects contraction as the sequestered SR calcium load influences the strength of 
subsequent contractions.  
Figure 1 shows the general process of calcium handling for cardiac myocyte 
contraction and relaxation. Depolarization across the sarcolemma membrane opens L-
type calcium channels (LTCC), causing an influx of calcium into the sarcoplasm. This 
induces calcium release from the SR lumen through the ryanodine receptor (RyR) in a 
process termed calcium-induced calcium release (CICR). Sarcoplasmic calcium binds to 
troponin C on the myofilaments and a series of coordinated events exposes binding sites 
on actin, allowing myosin and actin to contract. Relaxation is produced by removal of 
calcium from the sarcoplasm though SERCA, plasma membrane calcium ATPase (PMCA), 
or the sodium/calcium exchanger (NCX). SERCA accounts for approximately 70% of 
calcium removal and readies the myocyte for subsequent contractions. 
Previous studies have demonstrated that calcium handling is altered in HF 
(Gwathmey, Copelas et al. 1987). End-diastolic cytosolic calcium levels are found to be 
elevated in human failing myocardium (Gwathmey, Warren et al. 1991, Beuckelmann, 
Nabauer et al. 1992). Multiple studies showed that SR calcium stores are decreased in 
human failing myocardium (Lindner, Erdmann et al. 1998, Piacentino, Weber et al. 2003) 
alongside a reduction in calcium uptake into the SR (Pieske, Maier et al. 1999). These 
changes are characterized by a blunted calcium transient with elevated sarcoplasmic 
baseline calcium, slower calcium release from the SR stores, reduced peak amplitude of 
release, and slower calcium reuptake rates 
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Figure 1. Schematic representation of calcium handling in the cardiac myocyte. 
Depolarization of the sarcolemmal membrane opens L-type calcium channels (LTCC), 
allowing calcium into the cell. The increase in intracellular calcium opens ryanodine 
receptors (RyR), releasing calcium from the SR stores and increasing the sarcoplasmic 
calcium concentrations further. The elevated intracellular calcium binds to 
myofilaments and activates contraction through the action of myosin. Relaxation is 
produced by removal of calcium through the plasma membrane calcium ATPase 
(PMCA), the sodium calcium exchanger (NCX), or sarco/endoplasmic calcium ATPase 
(SERCA). SERCA is inhibited by phospholamban (PLB), but this inhibition can be 
alleviated by phosphorylation of PLB through protein kinase A (PKA) or 
calcium/calmodulin-dependent protein kinase II (CaMKII). 
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 (Beuckelmann and Erdmann 1992, Piacentino, Weber et al. 2003). This results in 
weaker muscle contractions, longer time to relax, and reduced cardiac output. As the 
chief constituent of calcium handling, SERCA presents an attractive target for correcting 
disordered calcium handling as a possible treatment for HF. 
In the heart, SERCA is predominantly regulated through a 52 amino acid 
inhibitory peptide called phospholamban (PLB, Figure 1). PLB inhibits SERCA by reducing 
the apparent affinity for calcium, thus decreasing the SERCA calcium transport rate over 
the physiological range of calcium concentrations. Relief of inhibition by PLB can be 
overcome by phosphorylation of PLB at serine 16 by protein kinase A (PKA) or by 
calcium calmodulin protein kinase II (CaMKII) at threonine 17 (Tada, Kirchberger et al. 
1975, Plank, Pifl et al. 1983, Simmerman, Collins et al. 1986). SERCA is a primary target 
of beta-adrenergic signaling through PLB phosphorylation by PKA, and an important 
component for increasing both inotropy and lusitropy in response to demand for higher 
cardiac output. In addition to altering calcium sensitivity of the SERCA pump, some 
evidence suggests that PLB also increases the maximal rate of transport (Vmax). Studies 
show that when phosphorylated PLB is present Vmax is increased beyond what can be 
achieved in the absence of PLB (Antipenko, Spielman et al. 1997, Reddy, Cornea et al. 
2003). This may be an additional regulatory mechanism for enhanced calcium transport 
that uniquely relies on the presence of phosphorylated PLB. 
Evidence suggests that, in addition to regulation by PLB, SERCA activity may also 
be regulated by assembly into homo-oligomers. Data show that this could be an 
inhibitory mechanism where SERCA protomers form aggregates in the membrane that 
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have reduced ATPase activity (Voss, Jones et al. 1994, Mersol, Kutchai et al. 1995). Other 
experiments show that SERCA protomers form specific oligomers that may enhance 
calcium transport through cooperative mechanisms. It has also been suggested that 
phosphorylated PLB may be a requirement for this cooperative action (Negash, Chen et 
al. 1996). However, these models have not been widely adopted, in part because 
detergent-solubilized SERCA has been shown to couple hydrolysis of ATP with calcium 
transport (Dean and Tanford 1978, Vilsen and Andersen 1987). Whether these 
solubilization conditions produce only monomeric SERCA and whether homo-
oligomerization is a necessary component of activity is still not clear. This necessitates a 
greater understanding of calcium transport across the SR membrane. 
The SERCA/PLB regulatory complex may include additional partners that regulate 
SERCA function. Previous studies have shown that a mitochondrial anti-apoptotic 
protein HS-1 associated protein X-1 (HAX-1) interacts with PLB (Vafiadaki, Sanoudou et 
al. 2007). Data suggest that HAX-1 regulates cardiac performance by promoting 
formation of PLB monomers which readily inhibit SERCA. Further evidence supports cell-
survival mediated by the interaction between PLB and HAX-1. The exact role of this 
protein in the regulatory complex has not been fully fleshed out. 
An area of study that remains unresolved is how phosphorylation of the cytosolic 
domain of PLB causes relief of SERCA inhibition. Our previous work has examined two 
models that explain how PLB inhibition is relieved. The first model proposes that 
phosphorylation of PLB causes unbinding from SERCA; this frees up SERCA to actively 
pump calcium (James, Inui et al. 1989, Kimura, Kurzydlowski et al. 1997, Chen, Akin et al. 
6 
 
 
 
2006). Our own studies and studies by other groups have supported a second model 
where phosphorylated PLB remains bound to SERCA (Negash, Yao et al. 2000, Bidwell, 
Blackwell et al. 2011). Regardless of the mechanism for relief of inhibition, neither 
model provides a complete understanding for the role of PLB phosphorylation on 
altered SERCA calcium sensitivity. Previous studies by our group have shown that there 
is a small structural change upon phosphorylation (Hou, Kelly et al. 2008). 
We set out to examine the regulatory complex in more detail and investigate the 
role of homo-oligomerization on SERCA function. 
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CHAPTER TWO 
REVIEW OF RELATED LITERATURE 
SERCA is a member of the ion-motive P-type ATPase family, which includes 
transporters such as the Na+/K+-ATPase and the H+/K+-ATPase, and H+-ATPase (Apell 
2004). P-type ATPases establish and maintain important electrochemical gradients that 
drive many essential cellular processes. ATPases pump ions across membranes, usually 
against their concentration gradients, by utilizing energy from ATP. The P-type ATPase 
family is highly homologous and characterized by four important domains: the 
nucleotide binding domain (N), the actuator domain (A), the phosphorylation domain 
(P), and the transmembrane domain (TM). The soluble A-, N-, and P-domains sit within 
the cytosolic lumen, while the TM-domain anchors the ATPase in the appropriate 
membrane. Most members of the P-type ATPase family contain 10 transmembrane 
helices, which dictate ion specificity (Clarke, Loo et al. 1989, Toyoshima, Nakasako et al. 
2000, Bublitz, Poulsen et al. 2010). 
Discovery and characterization of SERCA 
Identification of an SR membrane calcium pump first came from ATP-dependent 
calcium uptake experiments in crude SR muscle preparations (Hasselbach and Makinose 
1961, Ebashi and Ebashi 1962). These preparations sequestered calcium in SR fractions 
and produced relaxation similar to that of application of a calcium chelator. Spin-
labeling of SR vesicles showed that SR membrane protein underwent conformational 
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changes in response to ATP (Landgraf and Inesi 1969, Coan and Inesi 1976). A defining 
feature of SERCA calcium transport was first described Inesi, that of calcium 
dependence on ATPase activity. At low calcium concentrations there is little ATPase 
activity. As calcium concentrations increase, the activity of SERCA increases until it 
reaches a maximal rate of transport at saturating calcium. An example of this is shown 
in figure 2 (black). Refinement of ATPase measurements later demonstrated 
cooperativity of the calcium binding process; the first calcium binds with low affinity and 
the second with high affinity (Inesi, Kurzmack et al. 1980). The range of calcium over 
which ATPase activity is sensitive occurs from about 30 nM to 2 μM, the approximate 
physiological range of calcium in muscle tissue between relaxation (low calcium) and 
contraction (high calcium). The calcium threshold for activation of SERCA essentially sets 
the resting sarcoplasmic calcium concentration. 
In 1970 David MacLennan isolated and purified SERCA from rabbit skeletal 
muscle. The purified protein possessed all the hallmarks of what was then known about 
SERCA: the requirement for Mg2+ and Ca2+, inhibition by the addition of EGTA, and 
inhibition by mersalyl. Additionally, ATPase activity was found to be dependent on an 
intact phospholipid membrane, indicating that this protein is a membrane protein 
(MacLennan 1970). The molecular weight of purified SERCA was determined to be 102 
kDa and partial trypsin digestions helped identify the site of ATP binding and other 
features of SERCA structure (Stewart and MacLennan 1976, Reithmeier and MacLennan 
1981). In 1985 the cDNA sequence was determined for rabbit skeletal muscle 
(MacLennan, Brandl et al. 1985). Later work identified a total of 11 different isoforms: 
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Figure 2. A representative ATPase activity curve for SERCA in the absence (black) or 
presence of PLB (red). As calcium concentrations increase, the ATPase activity increases 
up to a maximal level. PLB produces a characteristic rightward shift in this relationship. 
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 SERCA1a/b, SERCA2a/b/c, and SERCA3a-f (Brandl, Green et al. 1986, Burk, Lytton et al. 
1989, Lytton, Zarain-Herzberg et al. 1989, Gelebart, Martin et al. 2003, Bobe, Bredoux et 
al. 2004). SERCA1a is the predominant fast skeletal isoform and is the most studied 
isoform due to its abundance in skeletal muscle and ease of purification. SERCA2b is 
ubiquitously expressed in all cell types. SERCA2a is the cardiac isoform; however, it is 
also expressed in slow skeletal muscle. 
SERCA transport mechanism 
SERCA ion transport is broadly characterized by transitions between the calcium-
bound E1 state and the calcium-free E2 state. However, there exist many catalytic 
transitions between these two simplified steps. The mechanism of P-type ATPase ion 
translocation, termed Post-Albers cycle, was first described in the Na+/K+-ATPase 
(Albers 1967, Post, Hegyvary et al. 1972). Briefly, ions bind to the TM-domain followed 
by binding of ATP in the N-domain. This is followed by phosphoryl transfer from ATP 
that forms a phosphoanhydride intermediate with the P-type ATPase at a highly 
conserved aspartic acid residue located in the P-domain. Ion translocation is achieved 
through a series of concerted motions that come from the hydrolysis of ATP. These 
motions drive the ions through the TM-domain to the opposite side of the membrane 
where they are released. SERCA transports two calcium ions from the cytosol to the 
ER/SR lumen for every ATP hydrolyzed (Inesi, Kurzmack et al. 1978). In addition, SERCA 
countertransports 2 or 3 H+ ions (Yu, Carroll et al. 1993, Stokes and Green 2003). Figure 
3 illustrates a simplified Post-Albers scheme for SERCA. Many of these transitions have 
 
11 
 
 
 
 
Figure 3. A Post-Albers schematic representation of SERCA calcium cycling. SERCA in the 
E1 state (high calcium affinity) binds ATP and calcium on the cytosolic side. Hydrolysis of 
ATP produces a phosphoenzyme intermediate followed by transition to the low calcium 
affinity E2 state. Calcium is released into the SR lumen followed by loss of the phosphate 
group and a structural transition back to the E1 state. 
 
  
12 
 
 
 
 been characterized, yielding different rate constants for each step. Importantly, some 
of these transitions are faster than others, indicating a rate-limiting step. 
SERCA in disease 
Only two diseases have been identified specifically originating from mutations to 
SERCA. A number of mutations in skeletal SERCA1 isoform have been shown to cause 
Brody disease (Karpati, Charuk et al. 1986, Odermatt, Taschner et al. 1996). Brody 
disease is characterized by impaired muscle relaxation, cramping, and stiffness. 
Mutations in the SERCA2 gene have been linked to Darier’s disease, an autosomal 
dominant skin disorder (Dhitavat, Macfarlane et al. 2003). Despite mutations in the 
SERCA2 gene, these individuals do not display increased rates of cardiovascular disease 
or HF. It is important to note that knockout of cardiac SERCA is embryonic lethal, 
indicating that mutations that significantly alter SERCA function would not be tolerated 
(Periasamy, Reed et al. 1999). 
Alterations to cardiac SERCA expression and regulation during HF have been 
observed across a wide range of studies, underscoring the importance of this protein. 
SERCA protein and RNA expression have been observed to decrease in HF in guinea pigs 
(Kiss, Ball et al. 1995), rats (Komuro, Kurabayashi et al. 1989, de la Bastie, Levitsky et al. 
1990), rabbits (Nagai, Zarain-Herzberg et al. 1989), and even dogs (O'Rourke, Kass et al. 
1999). Whether changes in SERCA activity and expression are a cause of progression to 
HF or whether these changes are simply correlated with HF is a matter of some debate. 
However, when SERCA was overexpressed in various animal models of HF, cardiac 
function was improved, demonstrating the importance of this protein in cardiac 
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pathogenesis (Baker, Hashimoto et al. 1998, Miyamoto, del Monte et al. 2000, Davia, 
Bernobich et al. 2001). 
Evidence suggests that the alterations in SERCA expression seen in various 
animal models might not be present in human cardiomyopathies. Some studies of 
human myocardium have shown similar reductions in both SERCA mRNA levels 
(Mercadier, Lompre et al. 1990, Arai, Alpert et al. 1993) and protein expression 
(Hasenfuss, Reinecke et al. 1994). However, other studies have shown that, while mRNA 
levels are decreased, protein levels remain the same (Schmidt, Hajjar et al. 1999, 
Munch, Bolck et al. 2002). Patients with HF had similar levels of SERCA protein 
compared to those without HF; however SERCA activity was significantly decreased 
(Schwinger, Bohm et al. 1995). Additional animal studies corroborate this observation; 
Zarain-Herzberg et al. found that SERCA activity was reduced more than expected for 
the level of decrease in protein expression (Zarain-Herzberg, Afzal et al. 1996), 
suggesting that reduced SERCA function is not entirely due to decreased expression. A 
recent clinical trial utilized overexpression of SERCA to treat patients with HF but did not 
improve clinical outcomes, indicating that our understanding of SERCA function is 
incomplete. Development of such future therapies will require a better understanding 
of function and regulation to address the role of depressed SERCA activity in disease.  
Discovery and characterization of phospholamban 
Evidence for cyclic AMP-dependent kinase targeting the SR membrane was first 
described in the early 1970’s by multiple groups (Wollenberger 1972, Wray, Gray et al. 
1973, La Raia and Morkin 1974). A potential modulator of SERCA activity was discovered 
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when Arnold Katz’s group showed that cardiac SR preparations had increased rates of 
calcium uptake following phosphorylation by cyclic AMP-dependent protein kinase 
(Kirchberger, Tada et al. 1972). They later identified this phosphorylation as targeting a 
22 kDa SR membrane protein (Tada, Kirchberger et al. 1975). Arnold Katz’s wife 
suggested naming this protein phospholamban after the greek “phospho” (phosphate) 
and “lambano” (to receive) (Katz 1998). Later experiments utilized boiling and detergent 
to show that the phospholamban monomer is approximately 5-6 kDa (Will, Levchenko 
et al. 1978, Bidlack and Shamoo 1980). The original identification of the 22 kDa species 
was more accurately determined to be a stable homo-pentamer with a molecular 
weight of 25-30 kDa (Fujii, Kadoma et al. 1986, Wegener, Simmerman et al. 1986). PLB 
has also been observed as dimers, trimers, and tetramers on gels, however the 
monomer and pentamer are the predominant forms (Thomas, Reddy et al. 1998). It is 
thought that the pentamer is an inactive reserve pool of PLB, although some studies 
have suggested that the pentamer may form an ion pore or functional channel (Kovacs, 
Nelson et al. 1988, Oxenoid and Chou 2005). Förster transfer recovery experiments have 
shown that the pentamer is a highly stable complex that exists in dynamic equilibrium 
with the monomeric form of PLB, which binds to and inhibits SERCA (Kimura, Asahi et al. 
1998, Robia, Campbell et al. 2007). 
PLB is composed of an amino-terminal cytosolic alpha helix connected with a 
hinge region to a single-pass carboxy-terminal transmembrane alpha helix (Simmerman, 
Collins et al. 1986, Simmerman, Lovelace et al. 1989). Crystal structures show that the 
transmembrane region of PLB binds to a groove in SERCA formed by the M2, M4, M6, 
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and M9 helices of the TM-domain of SERCA (Akin, Hurley et al. 2013). This groove was 
also observed to be the site of binding by a PLB homologue, sarcolipin, in skeletal 
isoform SERCA1a (Toyoshima, Iwasawa et al. 2013, Winther, Bublitz et al. 2013). The 
cytosolic domain of PLB has not been resolved in crystal structures. NMR experiments 
have shown that this region possibly exists in equilibrium between different structural 
substates (Verardi, Shi et al. 2011).  
Stoichiometry of the SERCA/PLB regulatory complex 
Extensive cross-linking studies and X-ray crystallography have shown that a 
single PLB interacts with SERCA (James, Inui et al. 1989, Akin, Hurley et al. 2013, 
Toyoshima, Iwasawa et al. 2013, Winther, Bublitz et al. 2013). However, some evidence 
suggests that more than one PLB may interact with SERCA. Two-dimensional co-
crystallization of SERCA and PLB showed that the PLB pentamer can interact with SERCA 
(Stokes, Pomfret et al. 2006). Further studies showed that mutations promoting 
pentamer formation retained inhibitory function, indicating that this might be the active 
inhibitory state (Glaves, Trieber et al. 2011). Published co-crystallization studies also 
suggested a PLB:SERCA stoichiometry of 1:2 (Young, Jones et al. 2001). Co-
immunoprecipitation studies demonstrated that both PLB and SLN can simultaneously 
bind SERCA, possibly generating a superinhibitory complex (Asahi, Kurzydlowski et al. 
2002, Asahi, Sugita et al. 2003). These studies suggest a secondary binding site and a 
possible PLB:SERCA stoichiometry of 2:1. However, most studies support a model of a 
single PLB bound to SERCA in a 1:1 stoichiometry (Mueller, Karim et al. 2004). Mutations 
that enhance the monomeric form of PLB show an improved ability to inhibit SERCA, 
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suggesting that an oligomeric form of PLB is not required for inhibition (Kimura, 
Kurzydlowski et al. 1997). Previous measurements of fluorescently-labeled PLB and 
SERCA support the model of a single PLB in the regulatory complex (Robia, Campbell et 
al. 2007). Many of the studies examining the stoichiometry of the complex have 
employed unnatural experimental conditions, thus it may be beneficial to examine this 
stoichiometry in a native environment. 
Inhibition of SERCA by PLB 
PLB inhibits SERCA through physical interaction with SERCA. Inhibition of SERCA 
is relieved by PKA phosphorylation of PLB at serine 16 or CaMKII phosphorylation at 
threonine 17 (Le Peuch, Haiech et al. 1979, Simmerman, Collins et al. 1986). It is not 
clear whether this mechanism works by physical dissociation of PLB from SERCA (Chen, 
Akin et al. 2006, Akin, Chen et al. 2010) or whether the two proteins remain bound 
during phosphorylation of PLB (Li, Bigelow et al. 2004, Mueller, Karim et al. 2004, 
Bidwell, Blackwell et al. 2011). Previous work has shown that stimulation of the beta-
adrenergic cascade produces a robust phosphorylation of PLB at serine 16 (Tada, 
Kirchberger et al. 1975) that increases SERCA activity (Kranias, Garvey et al. 1985). 
Phosphorylation makes SERCA a predominant target of beta-adrenergic signaling in the 
heart and comprises an important response to demand for increased contractility. 
SERCA inhibition can also be relieved by phosphorylation of PLB at threonine 17, 
although this probably does not occur independently of PKA serine 16 phosphorylation 
in the heart (Plank, Pifl et al. 1983, Lindemann and Watanabe 1985, Simmerman, Collins 
et al. 1986, Mundina-Weilenmann, Vittone et al. 1996). Dephosphorylation of both sites 
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has been shown to be due to protein phosphatase-1 activity (Kranias and Di Salvo 1986, 
Steenaart, Ganim et al. 1992).  
As previously shown in figure 2, SERCA activity increases in response to 
increasing calcium concentration. PLB inhibits SERCA by decreasing the calcium 
sensitivity, resulting in a rightward shift in this relationship (red trace). In fact, the first 
experiment on calcium uptake in the cardiac SR took advantage of “half-maximal” 
calcium, thus being poised to observe the greatest possible difference between 
unphosphorylated and phosphorylated PLB (Kirchberger, Tada et al. 1972). As seen in 
figure 2, at calcium concentrations below the maximum ATPase rate, SERCA activity is 
reduced when PLB is present. Phosphorylation of PLB will reverse this effect such that 
the calcium sensitivity is shifted back to the left. 
The maximal calcium ATPase activity may also be altered by PLB. Studies have 
identified distinct roles for serine 16 and threonine 17 in regulating SERCA (Mattiazzi, 
Hove-Madsen et al. 1994). Maximal calcium uptake rate (Vmax) increased in the presence 
of CaMKII phosphorylation (Mattiazzi, Hove-Madsen et al. 1994, Mundina-Weilenmann, 
Vittone et al. 1996). One of these studies suggested that Vmax changes were specific to 
CaMKII, while PKA phosphorylation only altered calcium sensitivity and not Vmax 
(Mattiazzi, Hove-Madsen et al. 1994). Other groups have observed Vmax increases in 
systems phosphorylated by PKA. Antipenko et al. reported a 33 – 44% increase in Vmax 
upon stimulation with PKA in purified SR (Antipenko, Spielman et al. 1997). This was also 
observed by Reddy et al. in a reconstituted system and by Lu et al. in cardiac SR with 
nonionic detergent (Lu and Kirchberger 1994, Reddy, Cornea et al. 2003). Trieber et al. 
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provided evidence that interaction of PLB with SERCA enhances Vmax even in the 
absence of phosphorylation and Vmax was not further altered by phosphorylation 
(Trieber, Douglas et al. 2005). ATPase measurements in the presence of synthetic 
peptides provided a potential mechanism of SERCA inhibition by PLB. Expression of the 
cytosolic region of PLB (amino acids 1 – 31) only decreased the Vmax of SERCA while 
expression of the transmembrane region of PLB (amino acids 28 – 47) only decreased 
the calcium affinity, differentiating the role of these domains in calcium transport 
regulation (Sasaki, Inui et al. 1992). Tryptic digestion of the cytosolic domain of PLB 
enhanced Vmax, corroborating the functional role of the cytosolic domain in calcium 
transport (Lu, Xu et al. 1993). A variety of experiments have indicated a possible 
functional effect of PLB by alteration of Vmax although the exact mechanism by which 
PLB would alter Vmax has not been established. 
Careful examination of the maximum rate of calcium transport has shown 
evidence for increases in Vmax with PLB. This may serve as an additional mechanism for 
increased calcium transport in the presence of phosphorylated PLB. However, not all 
groups have observed changes in Vmax despite attempts to examine this effect. Morris et 
al. did not detect a change in Vmax following phosphorylation with PKA or with 
incubation of two antibodies that mimic the effects of PLB (Morris, Cheng et al. 1991). 
These results were corroborated in SR preparations from human myocardium, again 
showing the failure of an anti-PLB antibody to alter Vmax (Movsesian, Colyer et al. 1990, 
Movsesian 1992). Earlier work from Reddy et al. found that PLB had no effect on Vmax in 
skeletal SR preparations co-expressed with recombinant PLB. They observed that 
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expression of the recombinant cytosolic domain of PLB (residues 1 – 31) had no 
apparent effect even at molar ratios as high as 300:1 (Reddy, Jones et al. 1995). Other 
studies also reported similar failure of PKA- or CaMKII-mediated phosphorylation to 
increase Vmax (Odermatt, Kurzydlowski et al. 1996, Schwinger, Munch et al. 1999). The 
inconsistent results obtained from measurements of ATPase activity remains an 
unresolved problem in the field and necessitates further examination of this effect. 
Phospholamban in disease 
A few mutations to PLB have been observed to cause cardiovascular disease. A 
mutation of arginine 9 to cysteine results in dilated cardiomyopathy and early death 
(Schmitt, Kamisago et al. 2003). Our group has previously characterized this mutant as 
being particularly susceptible to oxidative stress, decreasing regulation of SERCA (Abrol, 
de Tombe et al. 2015). Another mutation, L39stop, leads to heart failure (Haghighi, 
Kolokathis et al. 2003). Previous work has shown that this results in mislocalization of 
PLB to the sarcoplasm, reducing physical interaction with SERCA (Abrol, Smolin et al. 
2014). Deletion of arginine 14 was found in a family with hereditary HF (Haghighi, 
Kolokathis et al. 2006). More recently mutation of arginine 25 to cysteine was shown in 
a familial pedigree with dilated cardiomyopathy (Liu, Morales et al. 2015). These 
mutations to PLB underscore the importance of proper SERCA regulation and highlight 
the role of SERCA in cardiac pathogenesis. 
Evidence suggests that PLB protein expression does not change during the 
progression to HF (Munch, Bolck et al. 1998, Huang, Wang et al. 1999). However, studies 
suggest that phosphorylation of PLB is decreased in HF (Huang, Wang et al. 1999, 
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Schwinger, Munch et al. 1999). Measurements of protein expression in rats with 
congestive HF found that SERCA:PLB and pentamer:monomer ratios were preserved 
while phosphorylation of PLB at serine 16, but not threonine 17, was decreased (Sande, 
Sjaastad et al. 2002). These results also showed no change in SERCA expression. 
The decrease in PLB phosphorylation alone could explain the reduced SERCA 
activity observed in HF, however, multiple studies show a decreased responsiveness to 
stimulation by either PKA or CaMKII in failing myocardium. Schmidt et al. observed a 
decreased activation of SERCA in response to either PKA or CaMKII, suggesting that 
phosphorylation alone could not account for the decreased activity (Schmidt, Hajjar et 
al. 1999). Schwinger et al. found that PKA phosphorylation of failing human myocardium 
corrected the differences in calcium sensitivity, but a significant decrease in Vmax 
persisted (Schwinger, Munch et al. 1999). Blockade of phosphatase activity with okadaic 
acid reversed the loss of PLB phosphorylation but did not fully restore calcium transient 
amplitudes and rates of relaxation (Huang, Wang et al. 1999). The results seen in these 
studies show that the reduced PLB phosphorylation seen in HF does not fully explain the 
decrease in SERCA activity, suggesting that an additional mechanism may be involved. 
SERCA homo-oligomerization 
Multiple studies have provided evidence for the assembly of SERCA into homo-
oligomers. Early work on the skeletal SERCA isoform suggested that SERCA naturally 
forms oligomers in muscle tissue preparations. Electron microscopy of reconstituted 
purified SERCA in vesicles showed formation of tetramers (Vanderkooi, Ierokomas et al. 
1977). In 1984, Yamamoto et al. found that gel filtration of skeletal muscle SR 
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preparations produced two distinct fractions containing SERCA, the first at a molecular 
weight of approximately 150 kDa and the second at a molecular weight of 
approximately 360 kDa, suggesting formation of SERCA homo-dimers (Yamamoto, 
Yantorno et al. 1984). Careful analysis of the kinetic properties of calcium transport 
provided additional evidence for homo-dimerization (Mahaney, Albers et al. 2005, Chen, 
Yao et al. 2009). However, other kinetic studies detailing phosphoenzyme formation and 
decay support a model for SERCA homo-trimerization (Mahaney, Thomas et al. 2008). 
Higher order oligomerization has also been seen in time-resolved optical anisotropy 
measurements revealing the formation of SERCA aggregates in the presence of 
thapsigargin or melittin (Voss, Birmachu et al. 1991, Mersol, Kutchai et al. 1995). 
Many of the studies investigating oligomerization of SERCA have suggested that 
this may be an important regulator of SERCA function. Some studies have correlated 
oligomerization/aggregation with decreased SERCA catalytic activity. This observed 
inhibition by self-association could be relieved by phosphorylation, which is proposed to 
disrupt SERCA self association through charge reversal in the cytosolic region of PLB 
(Voss, Jones et al. 1994, Thomas, Reddy et al. 1998). Inhibitory molecules such as 
thapsigargin or melittin produced irreversible self association of SERCA (Voss, Birmachu 
et al. 1991, Mersol, Kutchai et al. 1995). However, other data suggest that SERCA 
oligomerization may be a mechanism for increased transport activity after relief of 
inhibition by adrenergic stimulation. In particular, saturation transfer electron 
paramagnetic resonance experiments indicated that phosphorylation of PLB reduced 
the rotational mobility of SERCA2a consistent with SERCA homo-oligomerization 
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(Negash, Chen et al. 1996). This interpretation is also supported by kinetic 
measurements of calcium transport that indicated SERCA2a dimerizes in the presence of 
phosphorylated PLB (Mahaney, Albers et al. 2005). Earlier work also demonstrated that 
SERCA-SERCA interactions altered responsiveness to ATP (Moller, Lind et al. 1980) or 
magnesium (Yamamoto, Yantorno et al. 1984, Vilsen and Andersen 1987). 
Significantly, the kinetic data suggested conformational coupling of SERCA 
protomers into a single functional unit to increase the rate of calcium transport. In this 
model energetically unfavorable structural transitions of one SERCA protomer are 
assisted by coupling them to energetically favorable conformational changes of another 
protomer. Examination of different kinetic transitions of calcium transport revealed that 
some steps were enhanced beyond the rate constants of a single protomer (Mahaney, 
Albers et al. 2005). By reducing the barrier of the slow step the overall rate of calcium 
transport is increased. Radiation inactivation of SERCA showed a reduction in SERCA 
activity that was greater than the inactivated fraction of SERCA, suggesting that the 
activity of SERCA is greater than the sum of its parts (Chamberlain, Berenski et al. 1983). 
An analogous experiment was performed by Chen et al., showing the ATPase activity 
was reduced more than would be expected from the molar ratio of WT to inactive 
SERCA (Chen, Yao et al. 2009). This process of conformational coupling enables SERCA to 
overcome catalytically unfavorable steps by coupling multiple SERCA protomers in a 
cooperative manner. These data may provide insight into the discrepancy between 
unchanged SERCA expression and depressed function. SERCA homo-oligomerization 
may be a key regulatory component of SERCA activity in addition to regulation by PLB.  
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Further precedence for SERCA homo-oligomerization comes from studies of 
other P-type ATPases. Early cross-linking of the Na+/K+-ATPase with copper and o-
phenanthroline yielded a tetramer. Interesting, only half of the ATPases were 
phosphorylated, suggesting that protomers may act cooperatively through alternating 
steps of the catalytic cycle (Askari and Huang 1980). Later work by Kunihiro Mimura et 
al. identified tetramer, dimer, and monomer fractions of this enzyme. The tetramer had 
half the ATPase activity of the monomer or dimer, suggesting a possible regulatory 
mechanism for self-association (Mimura, Tahara et al. 2008). Irradiation experiments of 
the gastric H+/K+-ATPase showed that dimerization was necessary for enzyme activity 
(Morii, Hayata et al. 1996). Despite the evidence for P-type ATPase oligomerization, 
these models have not been widely adopted as the monomeric forms are shown to 
possess ATP-dependent ion transport (Goormaghtigh, Chadwick et al. 1986, Andersen 
1989). 
Interaction of Hax-1 with the SERCA/PLB regulatory complex 
HAX-1 was originally identified in a yeast two-hybrid screen as a binding partner 
of HS1, a regulator of cell proliferation and death in lymphoid cells (Suzuki, Demoliere et 
al. 1997). Immunohistochemistry showed strong mitochondrial localization with some 
HAX-1 present in the ER membrane and nuclear envelope. Recent work has provided 
evidence for association of HAX-1 with the cytosolic domain of PLB (Vafiadaki, Sanoudou 
et al. 2007). Interestingly, western blotting of mouse ventricular myocytes from HAX-1 
overexpressing mice showed reduced SERCA protein levels (Vafiadaki, Arvanitis et al. 
2009). These studies found higher levels of HAX-1 when PLB was present in the heart 
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than when it was absent in a knockout mouse model. In addition, SERCA activity was 
more inhibited than the wild type mice, suggesting a regulatory mechanism for HAX-1 
that went beyond altering protein expression. In fact, phosphorylation of PLB abrogated 
interaction with HAX-1 as determined from co-immunoprecipitation experiments. Of 
note, HAX-1 was shown to interact with residues 16-22 on PLB. Fluorescence resonance 
energy transfer (FRET) experiments suggested that HAX-1 decreases PLB pentamer 
stability, increasing the pool of PLB monomers available to inhibit SERCA. This model 
was compatible with FRET measurements of the SERCA/PLB regulatory complex showing 
increased binding of PLB to SERCA (Vafiadaki, Arvanitis et al. 2009). The exact 
mechanism by which HAX-1 alters SERCA activity has not been resolved. It is possible 
that HAX-1 regulates SERCA by stabilizing or destabilizing SERCA homo-oligomers, thus 
altering the functional cooperativity. It would be prudent to determine whether this 
protein has a role in SERCA homo-oligomerization. 
Importance of SERCA 
The role of calcium handling in cardiovascular disease is evident. In addition to 
the data presented above, SERCA has been implicated in other diseases as well. 
Artemisinins are potent anti-malarial drugs used in treating multi-drug resistant malaria. 
Recently, they were determined to target PfATP6, a SERCA orthologue found in 
parasites that transmit malaria (Eckstein-Ludwig, Webb et al. 2003). Calcium is an 
important part of cell survival and growth and has been implicated in many signaling 
pathways (Yano, Tokumitsu et al. 1998, Apati, Janossy et al. 2003). Consequently, SERCA 
has been implicated in some forms of cancer and is being considered as a therapeutic 
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target (Denmeade, Jakobsen et al. 2003, Dubois, Vanden Abeele et al. 2013, Roti, 
Carlton et al. 2013). A greater understanding of the SERCA/PLB regulatory complex and 
mechanisms of activity may provide new interventions for disease. 
In the present study we set out to examine SERCA homo-oligomerization and 
regulation. We used photoactivatable cross-linking to investigate whether SERCA is 
oligomeric in cardiac myocytes. This work was extended to AAV-293 cells in order to 
quantify important parameters of structure and regulation. Using spectroscopic 
approaches, we quantified the stoichiometry of the putative oligomer and determined 
whether oligomerization was regulated by mechanisms known to be important 
determinants of SERCA activity. Various approaches were employed to examine how 
oligomerization can be pharmacologically or physically altered within the live 
membrane. Lifetime measurements allowed us to resolve discrete populations within 
the cell and to examine the interaction of PLB with SERCA and regulation in response to 
phosphorylation of PLB. Finally, functional measurements of SERCA activity helped 
provide insight into the physiological role of homo-oligomerization. 
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CHAPTER THREE 
MATERIALS AND METHODS 
A major enabling technology of the present study was the use of fluorescence 
resonance energy transfer (FRET). FRET provides many distinct advantages over other 
methods aimed at examining protein-protein interactions. It can be used in live cells so 
that the full physiological environment is preserved. Live cells also provide easy 
manipulation of physiological pathways and effectors. Beyond that, FRET techniques 
provide information about protein-protein affinity, structure, concentration, 
stoichiometry, quantitative measurements of distance, and identification of multiple 
populations of species. 
FRET is a process that describes the biophysical property of nonradiative energy 
transfer between two chromophores. This requires that the emission spectrum of the 
donor chromophore overlaps with the excitation spectrum of the acceptor 
chromophore (Tsien 1998). If the two labels are in close proximity the excited donor will 
transfer energy to the acceptor. FRET is very sensitive to distance and is most effective 
when the distance between donor and acceptor fluorescent proteins is between 25 and 
100 Å; the ideal range varies depending on the physical properties of the particular 
donor and acceptor selected. Figure 4 illustrates the FRET signal in response to distance 
changes for a CFP donor and YFP acceptor. At distances shorter than 25 Å the FRET 
signal is saturated and changes in distance will not alter the apparent FRET signal. At 
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 Figure 4. A simulation of the dependence of FRET efficiency on fluorescent protein 
separation distance (R) for cyan fluorescent protein (CFP) and yellow fluorescent protein 
(YFP). The Förster distance (R0) is the distance at which FRET efficiency = 0.5. 
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distances greater than 100 Å energy transfer cannot take place. This has the distinct 
advantage of generally limiting measurements to short distances where protein-protein 
interactions likely occur. There are many ways to measure FRET, some of which are 
outlined below. Each method has its own advantages and disadvantages, but, used 
together, these methods provide a substantial amount of information about the 
protein-protein interaction being studied.  
Molecular biology and cell culture 
Canine SERCA2a was labeled with mCerulean (Cer), enhanced green fluorescent 
protein (GFP), or enhanced yellow fluorescent protein (YFP). Labels were positioned at 
the N-terminus, between residues 508 and 509, or at the C-terminus. Canine PLB was 
labeled at the N-terminus with YFP or mCherry. Mutations were made to the PKA-
dependent phosphorylation site serine 16 of PLB to produce the nonphosphorylatable 
(S16A) and phosphomimetic (S16E) variants. FRET standards were used as positive 
controls in which Cer is fused to Venus fluorescent protein with a 5, 17, or 32 amino acid 
linker (C5V, C17V, or C32V) or Cer is fused between two Venus fluorescent proteins with 
linker sizes of five amino acids (VCV). All constructs were validated with nucleotide 
sequencing. Constructs were expressed by transient transfection of AAV-293 cells using 
the MBS mammalian transfection kit (Agilent Technologies). After 24 hours, the cells 
were trypsinized for one minute and plated on glass-bottom chambered slides (Matek) 
coated with poly-D-lysine. Cells were allowed to adhere to the slide for two hours 
before carrying out FRET measurements. 
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Progressive acceptor photobleaching 
Acceptor photobleaching is a technique that utilizes irreversible selective 
destruction of the acceptor chromophore through prolonged excitation. Once 
destroyed, the acceptor is no longer capable of quenching the donor and, if the donor 
and acceptor are at a distance capable of FRET, the donor intensity will increase. The 
stoichiometry of a molecular complex can be determined from the relationship between 
the donor and acceptor intensities over time. If this relationship is linear, then it 
indicates the donor- and acceptor-labeled complex exists as a dimer (N = 2). However, if 
this relationship is curved, then the complex exists as a higher order oligomer (N > 2) 
(Kelly, Hou et al. 2008). 
Acceptor photobleaching was carried out on an inverted microscope (Nikon) 
equipped with a 60X oil immersion objective with a numerical aperture of 1.49. A Lumen 
200 metal halide lamp (Prior) and excitation and emission filters (Semrock) were used to 
selectively excite the Cer and YFP channels and collect the emission signal. Images were 
collected using a back-thinned iXon 887 CCD camera (Andor Technology). Selection of 
the appropriate excitation and emission filters was managed by motorized filter wheels 
(Sutter Instruments). Cells were imaged every 10 seconds for 500 seconds and YFP was 
selectively photobleached by exposure to YFP excitation (504/12 nm) in the time 
between each image. The photobleaching power at the sample was approximately 1.59 
nW/μm2. Images were analyzed in the MetaMorph software program by manual 
selection of the cell fluorescence area. The average intensity values of the fluorescent 
area of the cell over time were normalized to the prebleach intensity using the 
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equation: F/F0 = (F-Fbg)/(F0-F0bg), where F is the fluorescence intensity, F0 is the 
prebleach fluorescence intensity, and Fbg and F0bg are the background fluorescence 
signals. Figure 5 shows a representative field of cells expressing Cer-SERCA and YFP-PLB 
before and after the photobleaching process. 
Acceptor-sensitized emission FRET 
We utilized acceptor-sensitized emission FRET as a way of measuring protein-
protein affinity and structure. This method allows FRET to be calculated from images of 
the donor and acceptor intensities with their respective excitation as well as a third 
image that captures the acceptor emission with donor excitation. It does not require 
long collection times such as needed with acceptor photobleaching. This allows a large 
number of cells to be quantified in a relatively short time period. Previous studies have 
shown that acceptor-sensitized FRET is consistent with other methods (Hou, Kelly et al. 
2008, Kelly, Hou et al. 2008, Hou and Robia 2010).  
Acceptor-sensitized FRET was performed on a Nikon inverted microscope 
equipped with a 40X NA dry objective. A motorized stage surveyed 120 individual 
locations and collected 150 ms exposures of the intensity of Cer emission following Cer 
excitation (Cer), YFP emission following YFP excitation (YFP), and YFP emission following 
Cer excitation (FRET). The 120 images for each condition were stitched together into a 
single montage image. Fluorescence intensity was measured by a multi-wavelength cell 
scoring application (MetaMorph). The background threshold was set to 110 counts. Cell 
size criteria were limited to 9 – 19 μm in diameter. FRET efficiency was calculated using 
the equation E = G/(G+4.6 x FCer) where G is an instrumental correction factor defined by 
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Figure 5. Representative images of AAV-293 cells expressing Cer-SERCA and YFP-PLB 
before photobleaching (pre-bleach) and after photobleaching for 10 minutes (post-
bleach). Note the decrease in YFP intensity and concomitant increase in Cer intensity as 
the donor and acceptor are close enough for FRET. 
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 the equation G = FFRET – a x FYFP – d x FCer. FFRET, FYFP, and  FCer are the cell average 
fluorescence intensities for the FRET, YFP, and Cer channels, respectively, and G is the 
FRET intensity corrected for bleed through of the donor (d) and acceptor (a) channels. 
The donor bleed-through constant was calculated by imaging cells that only expressed 
the donor and dividing the resulting FRET image by the donor image. The acceptor 
bleed-through was similarly calculated from cells that expressed only the acceptor and 
dividing the resulting FRET image by the acceptor image. The bleed through constants a 
and d were determined to be 0.085 and 0.737, respectively on our experimental setup.  
Each cell that expressed both Cer and YFP at a level above background threshold 
was plotted as percent FRET over the range of expressed protein concentration, as 
determined by the fluorescence intensity of the YFP channel (expressed in arbitrary 
units). The plotted data were fit by a hyperbola using the equation: FRET=FRETmax*X/(Kd 
+ X) where X is the measured YFP intensity, FRETmax is the maximum FRET, and Kd is the 
apparent dissociation constant of the donor- and acceptor-labeled proteins for each 
other. 
Fluorescence lifetime measurements 
 Fluorescence lifetime decays were collected using a Nikon Eclipse Ti inverted 
microscope equipped with a 60X NA water immersion objective. GFP was excited using a 
supercontinuum laser pulsed at a rate of 20 MHz (Fianium) and a 482/18 nm bandpass 
filter (Semrock Inc.). The fluorescence emission was passed through a dual band 
bandpass filter (523/610) and dichroic filter in the microscope (488/561 nm) and a 50 
μm confocal pinhole. The emission was then directed through a 525/50 nm bandpass 
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filter to an avalanche photodiode (Micro Photon Devices) using a dichroic beamsplitter 
(565 nm, Chroma).  
Fluorescence lifetime measurements were obtained from AAV-293 cells 
expressing GFP-SERCA alone or GFP-SERCA with mCherry-PLB. The level of expression of 
fluorescently labeled proteins in each cell was determined by using a 500 mm focal 
length planoconvex lens in a flip mount to defocus the excitation beam (560/14 nm) of 
the supercontinuum laser in order to excite the entire cell. The area of excitation at the 
Z-position of the cell was calculated to be 30 μm in diameter (approximately the size of 
one cell). The emitted fluorescence of mCherry-PLB was detected using a 640/50 nm 
bandpass filter and a CCD camera (CoolSNAP K4, Photometrics). The average 
fluorescence intensity of the cell (expressed in arbitrary units) was used as an index of 
the protein concentration. After each image was obtained, the lens was removed from 
the path and time correlated single photon counting was performed using single point 
excitation and confocal detection using the avalanche photodiode. Photons were 
collected until the peak of the decay reached a minimum of 104 photons. 
Fluorescence decays obtained from each cell were analyzed independently by 
tail fitting with a one- or two-component exponential decay from 3.5 ns using the 
SymPhoTime 64 software (Picoquant Photonics). The amplitude parameter was 
constrained to values between 0% and 100%. The tau parameter was compared to the 
average fluorescence intensity of mCherry-PLB for each cell measured with the CCD 
camera to determine the dependence of fluorescence lifetime on protein expression. 
Two-component analysis of GFP-SERCA fluorescence decays was performed by fixing 
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one lifetime to the donor-only tau in order to limit the number of floating parameters. 
FRET efficiency (E) was calculated using the equation: E = 100 x (1-τDA/τD), where τDA is 
the lifetime of the donor in the presence of acceptor and τD is the lifetime of the donor-
only sample. Distance measurements were calculated from the relationship R = R0(E
-1 – 
1)1/6, where R0 is the Förster distance for the GFP/mCherry pair (5.31 nm) and E is the 
average FRET efficiency from the lifetime measurements, assuming a random 
orientation factor (κ2 = 2/3). 
Photon counting histogram (PCH) analysis 
 AAV-293 cells expressing GFP-SERCA were cross-linked and separated out using 
SDS-PAGE as detailed below. Monomeric SERCA (135 kDa) and cross-linked SERCA (301 
kDa) were excised from the polyacrylamide gel and soaked in PBS for three hours at 
room temperature. Fluorescence correlation spectroscopy (FCS) was used to determine 
the concentration of GFP-SERCA of the gel eluants and the samples were diluted in 
order to compare equal concentrations of the eluted species in the subsequent PCH 
analysis. Photon counting was performed with a PicoHarp 300 TCSPC module 
(PicoQuant Photonics). FCS data were collected until the peak of the fluorescence decay 
had reached 104 photons. Histograms were generated in the SymPhoTime 64 software 
using a bin width of 0.2 ms and exported to Globals Software for Spectroscopy and 
Images (LFD, University of California, Irvine). PCH brightness analysis was performed 
using a one-photon, three dimensional Gaussian-Lorentzian model with one- or two-
species minimization. 
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Co-immunoprecipitation 
 Co-immunoprecipitation was performed in cells expressing GFP-SERCA2a and 
cMyc-SERCA2a at a molar plasmid ratio of 1:1. The cells were detached with a cell 
scraper in PBS and centrifuged at 500 G for five minutes. The supernatant was aspirated 
and the pellet was resuspended in cell lysis buffer containing 150 mM NaCl, 50 mM Tris, 
1% Nonidet-P-40, and EDTA-free protease inhibitor cocktail at pH = 8.0. The suspended 
pellet was incubated at 4 °C on a shaker for 20 minutes and then centrifuged at 13,000 
G for 10 minutes at 4 °C. The supernatant was transferred to a new centrifuge tube and 
incubated overnight at 4 °C with mouse anti-cMyc antibody (Clontech Laboratories, Cat. 
#631206) or mouse non-specific IgG antibody (Sigma-Aldrich, Cat. # I5381). The resulting 
immunocomplex was transferred to a new microcentrifuge tube containing protein-G 
magnetic Dynabeads. The sample was incubated for one hour at room temperature and 
then washed four times with cell lysis buffer. The final solution containing the beads was 
incubated at 55 °C for 10 minutes in 1% SDS with beta-mercaptoethanol to elute the 
bound protein. The resulting protein was separated out using SDS-PAGE and western 
blotting. 
Photoactivatable chemical cross-linking  
 Left ventricular cardiomyocytes were isolated from adult New Zealand white 
rabbits by a core facility as previously described (Domeier, Blatter et al. 2009). All animal 
protocols were approved by the Loyola University Institutional Animal Care and Use 
Committee. Myocytes were permeabilized for two minutes with 100 μg/mL saponin 
(Sigma-Aldrich) in a potassium-free relaxing solution containing: 100 mM NaCl, 5 mM 
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MgCl2, 2 mM EGTA, 10 mM Imidazole, 4 mM ATP, and 50 mM tris(2-
carboxyethyl)phosphine at pH = 7.0. A complete protease inhibitor cocktail (Santa Cruz 
Biotechnology) was added prior to the start of the experiment. The permeabilized 
myocytes were centrifuged for 5 minutes at 500 G at 4 °C. The supernatant was 
removed and replaced with potassium-free relaxing solution containing the 
photoactivatable cross-linker benzophenone-4-maleimide (BPM) (Sigma-Aldrich). BPM is 
a heterobifunctional cross-linker which contains a sulfhydryl-specific group and a 
photoactivatable group. The pellet was resuspended and incubated for one hour at 
room temperature. The suspension was then placed on ice and irradiated for 20 minutes 
by a long wave ultraviolet lamp set at 365 nm (UVP). A 2X cell lysis solution (300 mM 
NaCL, 100 mM Tris, 2% SDS, pH = 8.0) was added in equal volume to the suspension in 
preparation for western blotting. 
Protein quantification 
 Protein concentrations were determined from a bicinchoninic acid protein assay 
(Pierce). 20 μL of sample and water were loaded in triplicate on a 96-well plate. A 
standard curve was generated by using 2 mg/mL bovine serum albumin. Reagent 1 and 
2 were combined as per the provided protocol and 200 μL were added to each well. The 
plate was incubated at 37 °C for 30 minutes and then placed in an Epoch microplate 
spectrophotometer (BioTek Epoch) to measure the absorbance at 562 nm. 
Western blotting  
Samples were separated on a 4-15% polyacrylamide precast gradient gel (Bio-
Rad). The separated protein was transferred to polyvinylidene difluoride membrane at 
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100 V for two hours at 4 °C. The membrane was blocked in milk for one hour at room 
temperature followed by incubation of the primary antibody rabbit anti-GFP (1:2000; 
Life Technology), mouse anti-SERCA2 (1:2000, AbCam, Cat. # ab2817), or mouse anti-
cMyc (1:2000, Clontech Laboratories, Cat. # 631206) overnight at 4 °C. Blots were 
incubated with anti-mouse or -rabbit secondary antibodies conjugated to horseradish 
peroxidase for two hours at room temperature (1:20,000 dilution). The blots were 
developed using an electrochemiluminescence substrate (Perkin Elmer) and imaged 
using a ChemiDoc XRS+ (Bio-Rad). 
ATPase measurements 
SERCA enzymatic activity was quantified in cell homogenates by 
spectrophotometric measurement of the rate of NADH consumption in an enzyme 
coupled activity assay. AAV-293 cells expressing SERCA and/or PLB were detached using 
cold PBS and cell scraper. The cells were pelleted for 5 minutes at 4 °C and 500 G. The 
supernatant was aspirated and the cell pellet was resuspended in homogenization 
buffer (0.5 mM MgCl2, 10 mM Tris-HCl at pH = 7.5, and a complete protease inhibitor 
cocktail). The suspension was left on ice for 5 minutes and then homogenized with 30 
strokes of a Potter-Elvehjem homogenizer. An equal amount of 2X sucrose buffer (100 
mM MOPS at pH = 7.0, 500 mM sucrose, and 1 Complete protease inhibitor cocktail) 
was added followed by DNAse equal to 20% of the volume. 
A 5X buffer was made from 0.25 M MOPS, 0.5 M KCl, 25 mM MgCl2, 5.0 mM 
EGTA, pH = 7.0. This was used to make a 2X assay mix buffer consisting of 20% 5X buffer 
(by volume), 0.4 mM NADH, 1.0 mM PEP, 5.0 mM ATP, 10 IU/mL LDH, 10 IU/mL PK, and 
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0.00712 mg/mL calcium ionophore. A 2X sucrose buffer was made containing: 40 mM 
MOPS (pH = 7.0), 0.6 M sucrose, and 2 mM NaN3 at pH = 7.0 at room temperature. A 
range of 20X calcium solutions were made by combining 20 mM CaCl2 with ddH2O as 
detailed in Table 1. This 20X calcium solution was diluted in water and 2X sucrose buffer 
to yield a 4X calcium solution at 1X sucrose. The homogenate, 4X calcium solution, and 
2X assay mix were heated to 37 °C and then combined. The absorbance at 340 nm was 
read on a plate reader at 37 °C. The enzymatic reaction scheme for this protocol is 
detailed in figure 6. Purified rabbit fast-twitch skeletal SR preparations were obtained as 
described by Mueller et al. (Mueller, Karim et al. 2004). Purified pig cardiac SR 
membrane vesicles were obtained as described by Fruen et al. (Fruen, Bardy et al. 
2000). Both the skeletal and cardiac SR preparations were a gift from David D. Thomas 
at the University of Minnesota. 
The rate of the decrease in NADH absorbance was plotted against the calcium 
concentration. The data were fit with a Hill equation of the form:  
y = y0 + (Vmax – y0)(x
n/(kn+xn)) where y0 is the y offset, Vmax is the maximum rate of 
calcium transport, k is the calcium concentration at half maximal activity, and n is the 
Hill coefficient. 
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Table 1. The necessary volumes of 20 mM CaCl2 and ddH2O to produce a 20X calcium 
solution at 37 °C. 
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Figure 6. A schematic representation of the enzyme-linked ATPase assay. SERCA 
consumes ATP which is regenerated with pyruvate kinase and phosphoenolpyruvate 
(PEP). Pyruvate is turned into lactic acid with lactate dehydrogenase, oxidizing NADH in 
the process. The rate of decrease in absorbance at 340 nm is taken as an index of the 
rate of ATP consumption. 
 
 
 
41 
 
 
 
 
 
 
CHAPTER FOUR 
RESULTS 
SERCA homo-oligomerization 
Previous studies have shown that SERCA is capable of forming homo-oligomers 
in reconstituted lipid bilayers. To determine whether SERCA is oligomeric in live cells we 
performed co-immunoprecipitation in AAV-293 cells transiently co-transfected with 
GFP-SERCA and cMyc-SERCA. We used a buffer containing Nonidet P-40, which has been 
previously shown to preserve ER membrane protein interactions with SERCA and other 
regulatory partners (Han, Cai et al. 2011). Immunoprecipitation with anti-cMyc pulled 
down GFP-SERCA (Figure 7A). A control IgG antibody did not pull down either cMyc- or 
GFP-labeled SERCA, suggesting that SERCA protomers interact with each other. 
As an alternative approach, we investigated the interaction of SERCA protomers 
in the biosynthetic membranes of ventricular cells. We treated isolated rabbit cardiac 
left ventricular (LV) myocytes with saponin to selectively permeabilize the sarcolemma 
and performed photoactivatable cross-linking with BPM. BPM is a heterobifunctional 
cross-linker with a thiol-specific maleimide group and a photoactivatable benzophenone 
group capable of reacting with alpha carbons. This cross-linker is advantageous because 
the maleimide chemistry enables targeting of SERCA, which is estimated to contain 
more than 50% of the reactive thiols in the SR membrane by content (Viner, Williams et 
al. 1999). Furthermore, this benzophenone group does not depend on prior  
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Figure 7. Oligomerization of SERCA probed with co-immunoprecipitation (co-IP) and 
cross-linking. A) Co-IP of GFP-SERCA with Myc-SERCA. B) Western blot analysis of rabbit 
LV myocytes. Increasing concentrations of benzophenone-4-maleimide (BPM) decreased 
the amount of monomeric SERCA (band 1) and gave rise to two additional bands (Band 2 
and Band 3). C) Pretreatment of myocytes with 50 nM isoproterenol (iso) did not 
appreciably alter the SERCA electrophoretic pattern. D-F) Quantification of Bands 1, 2, 
and 3 relative to total SERCA. Values are mean ± SD from N = 3 independent blots. 
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identification of the binding interface or mutation of specific residues for reactivity and 
successful cross-linking.  
Western blots of the cross-linked LV myocytes were probed with a SERCA2 
primary antibody, revealing a single band at approximately 99 kDa (Figure 7B, Band 1) in 
keeping with the molecular weight of the SERCA monomer. Increasing concentrations of 
BPM caused a decrease in the relative amount of the SERCA monomer (Figure 7D) and 
yielded a new prominent band at 230 kDa (Figure 7B, Band 2). At the highest BPM 
concentrations (>100 μM) we observed a third band at 315 kDa (Figure 7B, Band 3). The 
contributions of these cross-linked species are quantified in figures 7D-F. 
Previous studies have suggested that phosphorylation of PLB at serine 16 may 
play an essential role in SERCA homo-oligomer formation. However, we did not observe 
a significant change in cross-linking after treatment of myocytes with 50 nM beta-
adrenergic agonist isoproterenol (iso) (Figure 7C). The data suggest that PLB 
phosphorylation does not alter BPM cross-linking of SERCA. The relative amount of the 
SERCA monomer increased with pre-incubation of increasing amounts of the detergent 
n-dodecylphosphocholine (DPC) (Figure 8A & B). It was noteworthy that high molecular 
weight species were still produced even after with pre-solubilization of apparent SERCA 
dimers with 1% DPC, suggesting a robust oligomeric interaction was present before the 
addition and activation of cross-linker. This may also indicate that previous studies using 
detergent-solubilized SERCA may not have contained 100% monomers.  
We attempted to identify the reactive cysteine on SERCA that may be 
responsible for cross-linking. Canine SERCA contains 26 cysteines. 10 of these are 
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Figure 8. Detergent solubilization of SERCA A) Pre-incubation with the detergent n-
dodecylphosphocholine (DPC) in 300 μM BPM increased the relative amount of 
monomeric SERCA (Band 1). B) Quantification of A.  
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 located in the TM domain and are likely inaccessible. Additionally, some of the 
cysteines positioned in the cytosolic domain form internal disulfide bridges and would 
not be reactive (Sharov, Dremina et al. 2006). We selected four reactive cysteines for 
mutation: C364, C498, C636, and C674. Individual mutations of these residues did not 
abrogate the cross-linking reaction, suggesting that the cross-linked species observed by 
western blotting are not a result of BPM interaction with these residues. This indicates 
that a different cysteine residue may be responsible for the cross-link or the cross-link 
may form from modification of another binding partner.  
To determine whether the high molecular weight bands seen by cross-linking 
contained multiple SERCA protomers or a single SERCA protomer cross-linked to another 
binding partner (Arvanitis, Vafiadaki et al. 2007, Vafiadaki, Sanoudou et al. 2007, Zhao, 
Li et al. 2015), we performed cross-linking of GFP-SERCA heterologously expressed in 
AAV-293 cells. Western blotting of the non cross-linked control sample showed GFP-
SERCA monomer at a molecular weight of 135 kDa (figure 9A). This +35 kDa shift in 
mobility compared to the unlabeled SERCA seen in figure 7B is consistent with the 
increase in molecular weight corresponding to attachment of a single GFP of 
approximately 30 kDa (Prendergast and Mann 1978). The cross-linked GFP-SERCA 
produced a second band at 301 kDa. We noted that this band was shifted by a value of 
+71 kDa, approximately equal to the molecular weight of two GFP molecules. The third 
band was not evident by western blot and is possibly indistinguishable from the second 
band or perhaps too large to enter the gel.  
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Figure 9. Brightness analysis. A) A representative western blot of GFP-SERCA cross-
linked in AAV-293 cells. The areas in blue demarcate the molecular weight range where 
samples were extracted from polyacrylamide gels. B) Photon counting histograms (PCH) 
for the two extracted fractions. Fits (shown in gray) were generated from the Globals for 
Spectroscopy software. C) Brightness measurements from PCH analysis of GFP-SERCA 
isolated from low molecular weight (black) and high molecular weight (red) fractions 
revealed an increased molecular brightness (ε) for the high molecular weight species. 
Molecular brightness values are mean ± SD from N = 3 individual gel slices (unpaired t-
test, p < 0.01). D) Soluble GFP brightness measurements in sodium dodecyl sulfate 
(mean ± SD). 
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The two GFP-SERCA SDS-PAGE bands were excised and eluted from 
polyacrylamide gels by incubation in PBS. The concentration of GFP-labeled SERCA was 
quantified by fluctuation correlation spectroscopy (FCS). FCS was used to generate an 
autocorrelation function for GFP-excited sample. The Y-axis intercept of the function 
(G(0)) is directly dependent on concentration of the sample. The G(0) values were then 
used to dilute the two GFP-SERCA samples down to equal concentrations. A photon 
counting histogram (PCH) was generated from the FCS data (Figure 9B) and used to 
calculate brightness. Brightness measurements revealed that the 135 kDa section of the 
gel containing monomeric GFP-SERCA had a molecular brightness of 2338  ± 76 counts 
per second per molecule (cpsm) while the cross-linked species (301 kDa) had a 
molecular brightness of 2832 ± 35 cpsm (mean ± SD) (figure 9C).  
Notably, the apparent molecular brightness of the cross-linked band was not 
increased 2-fold. Many factors may contribute to the apparently decreased brightness 
of the cross-linked species: A) BPM cross-linking may covalently modify some GFP and 
decrease or eliminate its fluorescence. B) UV exposure (for BPM activation) 
photobleaches some GFP molecules. C) Competition from endogenous SERCA creates 
some complexes where only a single SERCA has a GFP tag. D) Background fluorescence 
adds to the apparent molecular brightness of both the high and low molecular weight 
samples. E) SDS detergent presumably denatures a large number of the GFP molecules. 
All of these factors are expected to reduce the apparent difference between the low 
and the high molecular weight bands. Qualitatively, the data are taken to indicate 
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increased molecular brightness of the high molecular weight species consistent with an 
oligomeric complex of several GFP-SERCA protomers.  
To confirm that SDS itself does not alter GFP brightness, we performed 
brightness measurements on purified soluble GFP protein. Brightness slightly decreased 
with increasing concentrations of SDS, but was not significant (Figure 9D). The values 
obtained compared favorably to the brightness measurements from GFP-SERCA. 
Previous studies have shown that soluble GFP may have a slightly greater brightness 
than GFP attached to proteins, as the latter may be quenched in part by the bound 
protein (Nils 2010). 
Oligomeric structure and regulation 
We next sought to examine the quaternary structure and regulation of SERCA 
homo-oligomers in live cells using FRET techniques. To determine if attachment of 
fluorescent proteins alters SERCA function we performed ATPase assays on microsomes 
expressing SERCA. Cer-SERCA in the absence of PLB displayed calcium-dependent 
ATPase activity with sensitivity similar to skeletal SERCA1a (figure 10). Co-expression 
with YFP-PLB caused a rightward shift in this relationship; the magnitude of this change 
was similar to previous reports (Mueller, Karim et al. 2004). We also noted that 
expression of fluorescently-labeled SERCA and PLB targeted and localized to the ER/SR 
membrane correctly. 
We made FRET measurements from Cer-SERCA to SERCA labeled with YFP at the 
N-terminus (“N”), inserted before residue 509 (“509”), or fused to the C-terminus (“C) as 
diagrammed in figure 11A of a SERCA crystal structure: PDB 4KYT 
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Figure 10. Calcium ATPase measurements for skeletal SR microsomes (black) prepared 
from rabbit fast twitch muscle and microsomes prepared from AAV-293 cells expressing 
Cer-SERCA (red) or Cer-SERCA and YFP-PLB (blue). 
 
50 
 
 
 
 
 
Figure 11. FRET labeling strategy. A) FRET was measured from the N-terminus of Cer-
SERCA to another SERCA labeled with YFP at either the N-terminus, between amino 
acids 508 and 509, or at the C-terminus. B) All three acceptor-labeled positions 
produced FRET. The control FRET was measured using Cer-SERCA and non-fusion YFP. 
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 (Akin, Hurley et al. 2013). We observed FRET for all labeled positions (figure 11B); 
however, these values are averaged from many cells and so we could not infer relative 
positions of the different labeling sites. We selected the N-terminal labeling strategy for 
a more detailed analysis of the SERCA-SERCA interaction. Figure 12 shows the FRET 
values obtained from individual cells (dark gray) plotted as a function of whole-cell 
average fluorescence intensity, taken as an index of protein concentration. We used co-
transfection of Cer-SERCA and untethered YFP as a negative control (light gray). For 
clarity, the data were pooled and the values are superimposed with error bars 
representing SEM. FRET efficiency increased with increasing protein concentration and 
this relationship was well-described by a hyperbolic fit (black line), yielding two 
important parameters, the apparent dissociation constant (Kd) and maximum FRET 
(FRETmax). These two parameters are quantified as indices of the Cer-YFP separation 
distance and the complex binding affinity, respectively.  
FRETmax and Kd were not significantly different in the absence or presence of PLB 
(figure 13). Activation of the PKA pathway by application of 100 μM forskolin (an 
activator of adenylate cyclase) did not alter FRETmax or Kd, even with blockade of 
phosphatase activity with 100 μM 3-isobutyl-1-methylxanthine (“+PLB+F+I”), consistent 
with our chemical cross-linking measurements made in myocytes following stimulation 
with isoproterenol (figure 7C). We employed a monomeric mutant super-inhibitory 
phospholamban containing a triple cysteine to serine mutation (C36S/C41S/C46S) in 
order to test whether PLB oligomeric state altered SERCA homo-dimerization. We 
detected no significant effect on SERCA-SERCA FRETmax or Kd even with activation of the 
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Figure 12. Protein concentration dependence of FRET from Cer-SERCA2a to YFP-
SERCA2a (N) (black) or negative control Cer-SERCA2a to non-fusion YFP (red). Individual 
cells are shown in gray, with pooled data (mean ±SEM) in red or black. Data were 
modeled with a hyperbolic fit (lines). Maximum FRET (FRETmax) and the apparent 
dissociation constant (Kd) are calculated from the fit. 
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Figure 13. Apparent dissociation constants (Kd) and maximum FRET (FRETmax) values 
calculated from the hyperbolic fits of FRET data in the absence (-PLB) or presence of 
phospholamban (+PLBwt). Application of 100 μM forskolin and 100 μM 3-isobutyl-1-
methylxanthine (+PLB+F+I) did not alter the apparent affinity (Kd) of the dimer. A more 
monomeric form of PLB with three cysteines mutated to serine (SSS) did not alter the 
SERCA oligomer, even with application of forskolin and IBMX. Coexpression with non-
phosphorylatable (+PLB-S16A) or phosphomimetic (+PLB-S16E) PLB mutants had no 
appreciable effect. Alterations to calcium (2 mM) or ATP (4 mM) did not elicit any 
changes. Mean ± SEM, N = 3 independent experiments (no statistically significant 
differences between groups by one-way ANOVA). 
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 PKA pathway. Mutations to PLB at serine 16 to mimic (S16E) or prevent (S16A) 
phosphorylation also had no effect on these two parameters. Thus, the present data are 
not consistent with previous studies that indicated that PLB serine 16 phosphorylation 
altered SERCA homo-oligomerization (Negash, Chen et al. 1996).  
Previous studies have suggested that oligomerization may occur only during 
specific catalytic transitions in the ATPase cycle (Andersen and Vilsen 1985, Akin and 
Jones 2012). This may be a mechanism driven by binding and unbinding of homo-
oligomers. To investigate whether oligomerization is affected by SERCA conformational 
poise we measured FRET in cells permeabilized with saponin and bathed in solutions of 
defined composition. We did not observe any significant changes to FRETmax or Kd when 
calcium and ATP were removed or when calcium (2 mM) and/or ATP (4 mM) were 
present (figure 13). These results suggest that SERCA conformational poise does not 
alter SERCA homo-oligomeric structure or affinity, such as during active cycling. 
Previous studies have indicated that oligomerization may be enhanced by 
inhibitors such as thapsigargin (TG) and melittin as part of a regulatory mechanism 
(Mersol, Kutchai et al. 1995, Voss, Mahaney et al. 1995). We used a 2-color SERCA 
construct comprised of a donor fluorescent protein attached to the N-terminus (A-
domain) and an acceptor fluorescent protein positioned between amino acids 508 and 
509 (N-domain) (figure 14A) to determine if TG induces structural changes in the pump. 
Titration of TG reduced FRET by approximately 10%, indicating separation of the A- and 
N-domain and a more “open” conformation following binding by TG (figure 14B). This 
was in agreement with previous data from our laboratory 
55 
 
 
 
 
 
 
Figure 14. Effects of inhibitors on SERCA oligomerization. A) The labeling strategy for “2-
color” SERCA consisting of a Cer donor attached to the N-terminus (A-domain) and a YFP 
acceptor inserted between amino acids 508 and 509 (N-domain). Generated from the 
SERCA crystal structure 1IWO (Toyoshima and Nomura 2002). B) Titration of 
thapsigargin decreased the FRET between the N- and A-domain, indicating an increase 
in separation distance (Hill fit shown in red). C) Application of 10 μM thapsigargin to 
AAV-293 cells expressing Cer-SERCA and YFP-SERCA did not alter FRETmax or Kd. D) 
Treatment with 50 μg/mL saponin and/or 250 μM melittin did not alter FRET (mean ± 
SD). 
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 (Hou, Hu et al. 2012, Pallikkuth, Blackwell et al. 2013). Despite this large conformational 
change, we did not detect any alterations to the SERCA homo-dimer FRETmax or Kd 
(figure 14C). We also examined the effect of melittin (an active component in bee 
venom) on homo-dimerization. We found that melittin disrupted the cell membrane 
integrity; however the average FRET was not significantly altered by application of 250 
μM melittin (figure 14D). 
Previous work has identified HAX-1 as a regulator of the SERCA/PLB regulatory 
complex through stabilization of the PLB monomer. FRET experiments showed that 
SERCA/PLB FRET is increased in the presence of HAX-1 while PLB pentamer FRET is 
decreased (Vafiadaki, Arvanitis et al. 2009). We measured SERCA oligomer FRET in the 
absence and presence of HAX-1, but found no difference in the FRETmax and Kd 
parameters (figure 15A). We observed, however, that HAX-1 appeared to increase Cer-
SERCA and YFP-SERCA expression. To test whether HAX-1 increased expression of SERCA 
or PLB, we co-transfected HEK cells with HAX-1 and SERCA or PLB. Increasing molar 
ratios of HAX-1 resulted in dramatically increased protein expression levels of SERCA or 
PLB (figure 15B). The altered expression, however, did not alter the Kd or FRETmax 
parameters, suggesting that HAX-1 does not regulate SERCA-SERCA affinity or structure. 
To determine whether our measured SERCA-SERCA FRET was due to specific 
protein-protein interactions, rather than a consequence of non-specific protein 
crowding in the membrane, we measured Cer-SERCA/YFP-SERCA FRET in the presence 
of a third species of unlabeled SERCA (figure 16A). Unlabeled SERCA should act as a 
competitor if specific protein-protein interactions contribute to the detected FRET 
57 
 
 
 
 
 
 
 
Figure 15. Effect of HAX-1 on oligomerization. A) Co-expression of HAX-1 with Cer-
SERCA and YFP-SERCA did not alter FRETmax or Kd, however, an apparent increase in 
protein expression with HAX-1 was noted. B) This was further examined over a range of 
molar ratios of HAX-1 relative to YFP-PLB (mean ± SD). 
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Figure 16. FRET competition assay. A) FRET from Cer-SERCA and YFP-SERCA was reduced 
by coexpression of non-fluorescent SERCA. Values reflect the molar ratio of 
competitor:YFP-SERCA. B) FRETmax was decreased by competition with non-fluorescent 
SERCA (black) but not by PLB (blue). Hyperbolic fit shown in red. 
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 signal. The transfection ratio of Cer-SERCA to YFP-SERCA was kept at a constant molar 
ratio of 1:5 while increasing molar ratios of unlabeled SERCA were co-transfected. 
Increasing the molar ratio of unlabeled SERCA relative to YFP-SERCA caused a 
progressive decrease in FRETmax (figure 16B, black data points). This reduction in FRETmax 
was well described by a hyperbola (red fit), consistent with simple competition of 
unlabeled SERCA for the fluorescently labeled SERCA protomers in the oligomeric 
complex. The data suggest that the FRET observed here is due to a specific interaction 
between SERCA molecules. The residual FRET remaining at the highest competitor:YFP 
ratio tested was 3.5%, and is taken as an estimate of non-specific FRET between non-
interacting donors and acceptors. Notably, using PLB as a competitor did not alter the 
measured SERCA-SERCA FRET at any ratio tested (figure 16B, blue data points), 
consistent with the experiment shown in figure 13. We conclude that the presence or 
absence of PLB did not alter the constitutive oligomerization of SERCA under the present 
experimental conditions. 
We further sought to disrupt our FRET signal by titration of anti-SERCA 
antibodies, as this would provide a useful tool for separating SERCA homo-oligomers in 
the membrane. AAV-293 cells expressing Cer-SERCA and YFP-SERCA were subjected to 
permeabilization with saponin and incubation with anti-SERCA2 IID8 antibody (IID8, 
AbCam). Incubation of this antibody did not alter FRET even after incubation for nearly 
four hours (figure 17). We cannot draw a conclusion about the region of binding, as the 
exact sequence identity of the epitope is unreported. We also utilized crude test bleeds 
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Figure 17. FRETmax measurements of AAV-293 cells expressing Cer-SERCA and YFP-
SERCA. Cells were treated with saponin in the presence of increasing concentrations of 
anti-SERCA2 (IID8) antibody and incubated at room temperature for the indicated 
period of time (mean ± SD from N = 3 experiments per treatment). 
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 from rabbit sera targeting various peptides within the P-domain of SERCA. These were 
raised against the following peptide sequences: 
n-CATEQERTPLQQKLDEF 
n-CLGTRRMAKKNAIVRSLP 
n-YNEAKGVYEKVGEAT 
n-CPDLDIMNKPPRNPKEPL 
n-DPPRIEVASSVKL 
n-SLLRMPPWENIWLVGSI 
Incubation with sera from these rabbits did not alter the oligomeric FRET, suggesting 
that the P-domain is not involved in homo-oligomerization. 
SERCA homo-oligomeric stoichiometry 
To determine the oligomeric stoichiometry of SERCA, we performed progressive 
acceptor photobleaching with AAV-293 cells transiently expressing Cer-SERCA and YFP-
SERCA or Cer-SERCA and untethered YFP. Figure 18A shows the progressive decrease in 
YFP-SERCA emission (black) as YFP is selectively photobleached. This occurred with a 
concomitant increase in Cer-SERCA emission (blue) as the donor is close enough for 
FRET. Figure 18B shows the relationship between the changes in donor and acceptor 
intensities. The relationship was linear for Cer-SERCA + YFP-SERCA (black). The Cer 
intensity did not increase for a negative control expressing Cer-SERCA + untethered-YFP, 
demonstrating that this donor/acceptor pair is not interacting (red). The stoichiometry 
of the donor-acceptor complex is reflected in a comparison of the donor and 
fluorescence intensities (Li, Reddy et al. 1999). As an example, figure 19A shows that Cer 
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Figure 18. Acceptor photobleaching of the SERCA oligomer. A) Progressive acceptor 
photobleaching of YFP-SERCA (black) resulted in increased Cer-SERCA fluorescence 
(blue), indicating FRET. Mean ± SEM, N = 28 cells total from 3 independent experiments. 
B) Photobleaching of the SERCA homo-oligomer resulted in a linear increase in Cer 
intensity with decreasing YFP intensity (black). No increase in Cer-SERCA intensity was 
observed for non-fusion control (red). 
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Figure 19. The relationship of donor/acceptor fluorescence intensities during the 
process of photobleaching for a construct comprising A) one acceptor and one donor 
(C32V) or B) a construct comprising two acceptors and one donor (VCV). C) This 
relationship was also plotted for Cer-PLB and YFP-PLB, a well-known pentameric 
oligomer. Mean ± SD, N = 12 cells. Lines connect the first and last data points. 
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 fluorescence (plotted on the ordinate) increases linearly with the decrease in Venus 
acceptor fluorescence (plotted on the abscissa, decreasing from right to left over time) 
for a control construct (C32V) expressing a tethered donor and acceptor in a 
stoichiometry of 1:1. In contrast, a construct comprising a donor tethered to two 
acceptors (VCV) displayed significant curvature (figure 19B), since FRET persists after 
ablation of a single acceptor, and donor brightness only fully increases late in the 
photobleaching process when the last acceptors are photobleached. We observed 
similar curvature with FRET between Cer-PLB and YFP-PLB protomers in a pentameric 
complex (figure 19C). The linear relationship for the SERCA homo-oligomer observed in 
figure 18B is consistent with a single acceptor in the oligomeric complex, suggesting that 
SERCA forms homo-dimers. This relationship was linear over a wide range of protein 
concentrations, indicating that this is the predominant oligomeric state. Photobleaching 
did not provide evidence for formation of higher order oligomers or aggregates even at 
the highest protein concentrations. 
PLB interaction with SERCA 
The above results suggest that PLB does not modulate the physical interaction 
between SERCA protomers. We set out to determine whether PLB can interact with 
SERCA homo-dimers or whether PLB interacts with a separate pool of monomeric 
SERCA. Figure 20A shows co-localization of Cer-SERCA and YFP-PLB in AAV-293 cells. 
Acceptor-sensitized FRET measurements of the complex showed a protein-dependent 
binding that saturated at approximately 25% FRET (figure 20B). Acceptor 
photobleaching revealed a linear donor:acceptor relationship consistent with a single 
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Figure 20. FRET measurements of the SERCA/PLB regulatory complex. A) Co-expression 
of Cer-SERCA2a and YFP-PLB in AAV-293 cells. B) Acceptor-sensitized FRET 
measurements of the regulatory complex. Hyperbolic fit shown in red. C) Acceptor 
photobleaching of the regulatory complex, indicating the presence of a single acceptor 
(YFP-PLB). Blue line connects the first and last data points. Data are shown as mean ± 
SD. 
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YFP-PLB acceptor in the complex (figure 20C), but this assay cannot rule out the 
possibility of multiple Cer donors in the complex. In theory, one could swap the 
fluorophores and perform FRET from Cer-PLB to YFP-SERCA to determine if the inverse 
FRET experiment also shows a linear relationship (as in a 1:1 hetero-dimer) or a curved 
relationship consistent with multiple SERCA protomers in the regulatory complex. 
However, this is impractical for these proteins as PLB also avidly forms homo-
pentamers, so most Cer-PLB donors would not participate in FRET, complicating the 
analysis. As an alternative, we probed the stoichiometry of the SERCA-PLB complex with 
fluorescence lifetime analysis, which can reveal subpopulations of donors with different 
FRET efficiencies. Figure 21A depicts the labeling strategy, with a GFP donor fused to the 
N-terminus of SERCA and an mCherry acceptor fused to the N-terminus of PLB. The 
crystal structure of the regulatory complex is taken from Akin et al. and did not reveal 
the PLB cytoplasmic domain (Akin, Hurley et al. 2013). As such, the actual position of the 
PLB N-terminus and mCherry fluorescent protein tag are unknown.  
Figure 21B shows the fluorescence decay of GFP-SERCA in the absence (black) or 
presence of mCherry-PLB (red). The decrease in the GFP fluorescence lifetime in the 
presence of mCherry-PLB (red) is consistent with FRET from GFP to mCherry. Decays 
were obtained from 99 cells and analyzed by fitting with a single component 
exponential decay. The fluorescence lifetime of GFP-SERCA alone (τD) was 2.56 ± 0.02 
ns. The fluorescence lifetime (τDA) of GFP-SERCA decreased with increasing mCherry-PLB 
protein expression to a minimum value (figure 22A). FRET was quantified according to 
the relationship FRET = 100 x (1 - τDA/τD) where τD is measured from cells expressing 
67 
 
 
 
 
 
 
Figure 21. SERCA/PLB regulatory complex fluorescence lifetime measurements. A) 
Labeling strategy for FRET from GFP-SERCA (grey) to mCherry-PLB (red). B) 
Representative fluorescence decays of GFP-SERCA in the absence (black) or presence of 
mCherry-PLB (red). The decay was shortened by coexpression of mCherry-PLB, 
indicating FRET. Exponential tail fits are shown in gray. 
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Figure 22. Fluorescence lifetime fitting. A) A single component exponential fit of the 
fluorescence lifetime shows a decrease in tau (τ) with increasing protein expression. 
Each point represents a measurement from an individual cell. N = 99 individual cells. 
Hyperbolic fit shown in red. B) FRET (calculated from data in A) increased with protein 
expression. Hyperbolic fit shown in red. C) Reduced chi-squared (χ2) values for 1-
component fits worsened as protein expression increased. Reduced χ2 was improved for 
a two-component fit. Shown with linear fits. D) Average Reduced χ2 values obtained 
from fitting the fluorescence decay to a 1-, 2-, or 3-component exponential decay. 
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GFP-SERCA only. Figure 22B shows that FRET increased with acceptor expression in a 
hyperbolic relationship to a maximum of 22.2% FRET, a value that is in harmony with 
the acceptor-sensitized FRET measurements above (figure 20B) and previous steady-
state FRET measurements from our lab (Hou and Robia 2010, Bidwell, Blackwell et al. 
2011).  
We observed that the single component exponential decay goodness of fit 
(reduced χ2) became progressively worse as the level of protein expression increased 
(figure 22C, black), suggesting that a single species model was a poor description of the 
complex at higher protein expression levels. Reduced χ2 was significantly improved by a 
two component exponential model, which was a good description of the data over a 
wide range of concentrations (figure 22C, red). Fitting to a third component did not 
improve χ2 (figure 22D). Fit residuals for one- and two-component models show that the 
GFP-SERCA alone was sufficiently described by a one-component model, but GFP-SERCA 
in the presence of mCherry-PLB was effectively described only by a two-component 
model (figure 23). Interestingly, the two-component exponential fit yielded a long 
lifetime (τL) of 2.48 ± 0.09 ns that was very similar to the GFP-SERCA only lifetime of 2.56 
± 0.02 ns and a short lifetime (τS) that averaged 1.37 ± 0.09 ns. The data are consistent 
with the existence of a sub-population of high FRET donors (τS) and another 
subpopulation of non-FRET donors (τL). Figure 24A is a cell-by-cell measurement of the 
short lifetime (τS) component. We calculated FRET from the high FRET donors (τS) over 
the range in protein expression and found that the values for this population did not 
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Figure 23. Representative residual plots for 1- or 2- component exponential models of 
the fluorescence decay for GFP-SERCA alone (black) or in the presence of mCherry-PLB 
(red). 
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 display protein concentration dependence as observed in the one-species exponential 
model (figure 24B). 
Figure 24C shows the FRETmax value obtained from the 1-species model and the 
two populations obtained from the 2-species model. The average FRET efficiency of the 
high FRET population (Pop. 2) was 46.3 ± 3.9%. This corresponds to an apparent probe 
separation distance of 54 Å. Interestingly, the present estimate of SERCA-PLB FRET 
efficiency is nearly twice that determined from acceptor-sensitized FRET measurements. 
Our previous steady state measurements of the SERCA-PLB regulatory complex (which 
cannot distinguish subpopulations of donors) yielded distance estimates of 10 Å longer 
than the present time-resolved quantification. Previous measurements thus 
overestimated the apparent separation distance between the N-terminus of SERCA and 
the cytosolic domain of PLB; these two domains are closer than we previously reported. 
Two-component fitting also revealed the relative proportion of the high and low 
FRET populations. As expected, the percentage of donors with short lifetimes (high 
FRET) increased with protein expression at the expense of the long lifetime (non-FRET) 
species. However, it is noteworthy that the percentage of high FRET donors approached 
but did not exceed 50% of the total (figure 24D). Thus, the numbers of high FRET and 
non-FRET donors converged to approximately equal size populations. This phenomenon 
may be explained by a model in which a single SERCA protomer undergoes FRET with 
PLB while a second bound SERCA protomer does not. At low levels of protein expression 
most SERCA protomers are likely not engaged in dimerization, thus the non-FRET 
population (τL) dominates. As protein expression increases, the SERCA protomers are 
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Figure 24. Bi-exponential decay fitting. A) The short lifetime values from 2-component 
exponential decays were consistent across a large range of protein expression levels. B) 
The short lifetime values were used to calculate FRET, which remained constant with 
increasing protein expression. C) The FRETmax value calculated from the 1-component 
FRET curve in figure 22 and the FRET values for the long lifetime (Population 1) and 
short lifetime (Population 2) species. D) The relative contributions (amplitude) of the 
short and long lifetimes. 
 
  
  
73 
 
 
 
able to “find” each other, thus producing a FRETing SERCA and a non-FRETing SERCA 
bound to PLB in a 2:1 stoichiometry. At saturated binding this would indicate equal 
contributions from the two SERCA populations. 
To determine whether phosphorylation of PLB alters interaction with SERCA, we 
measured fluorescence lifetime in AAV-293 cells co-transfected with Cer-SERCA and 
YFP-PLB containing either the S16A (non-phosphorylatable) or S16E (phosphomimetic) 
mutations. Fluorescence lifetime imaging microscopy showed a homogenous 
distribution of the measured lifetime, suggesting that there are not distinct sub-
populations of molecules with different lifetimes at the optical resolution of our 
microscope (figure 25A). The whole-cell average FRET from Cer-SERCA to YFP-PLB-S16A 
measured using fluorescence lifetime was 27.1%, which was in agreement with previous 
ensemble measurements. We noted again, however, that both S16A and S16E 
fluorescence decays were better described by a bi-exponential model, yielding a non-
FRET population (Pop. 1) and a high-FRET-population (Pop. 2). This suggests that non-
phosphorylated and phosphorylated PLB both remain bound to the SERCA homo-dimer. 
The average FRET for population 2 was 44.7 % ±6.15 for non-phosphorylatable PLB and 
32.7 % ±3.51 for phosphomimetic PLB (Figure 25B). The average amplitudes of the low 
FRET and high FRET populations were 66.9% and 33.1% respectively for PLB-S16A and 
52.5% and 47.5% respectively for PLB-S16E. We noted that FRET decreased from 44.7% 
to 32.7% upon phosphorylation. The magnitude of this change was twice what we 
previously reported from whole cell FRET measurements (Hou, Kelly et al. 2008), 
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Figure 25. Lifetime measurements with PLB phosphorylation. A) Fluorescence lifetime 
images in AAV-293 cells expressing donor-labeled Cer-SERCA alone or Cer- SERCA with 
YFP-PLB-S16A. Note that the color-scale in these images represents the fluorescence 
lifetime (in nanoseconds) and not the color of the emitted light. B) FRET was calculated 
from 2-component exponential decays as in figure 23 for Cer-SERCA in the presence of 
YFP-PLB-S16A (non-phosphorylatable) or YFP-PLB-S16E (phosphomimetic). Mean ± SD, N 
= 12 cells, unpaired t-test, p < 0.01. 
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suggesting that phosphorylation of PLB moves the cytosolic domain more than 
previously thought. 
SERCA function 
To examine the functional effects of SERCA in the presence of PLB, we received 
purified skeletal SR from rabbit fast twitch muscle and cardiac SR from pig hearts as a 
gift from Dr. David D. Thomas. We performed ATPase assays on the preparations and 
observed a characteristic rightward shift in the calcium sensitivity for PLB-containing 
cardiac SERCA (figure 26A). We noted, however, that the Hill coefficient for 
cooperativity of activation by calcium was increased for the cardiac tissue (nH = 2.64) 
relative to the skeletal tissue (nH = 1.55), suggesting that an additional cooperative 
mechanism may be present with PLB. 
To investigate the functional coupling of SERCA we mutated the aspartic acid 
residue responsible for formation of the phosphoenzyme intermediate to alanine 
(D351A). This mutant has been previously characterized as a catalytically inactive 
enzyme that is still capable of binding calcium (Akin, Chen et al. 2010). Co-expression of 
wild type (wt) SERCA with mutant SERCA would be predicted to alter enzyme activity if 
there is a functional coupling mechanism present that relies on ATPase activity of both 
paired protomers. We expressed equal amounts of wt and D351A SERCA in molar ratios 
of 1:1 with PLB-S16A or PLB-S16E in AAV-293 cells and prepared microsomes. 
Measurements of the ATPase activity showed calcium sensitivity with a rightward shift 
for the non-phosphorylatable PLB-S16A (figure 26B). We also noted that at saturating 
calcium (pCa = 5.0) the sample with S16E appeared to have a larger Vmax, but this was 
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Figure 26. Calcium-dependent ATPase measurements. A) Normalized ATPase 
measurements for microsomes purified from skeletal SR from rabbit fast twitch muscle 
and cardiac SR from pig hearts. Data points are the mean from N = 3. Hill fits shown as 
lines. B) ATPase activity from microsomes transfected with equal amounts of wild type 
and D351A SERCA in a 1:1 molar ratio with PLB-S16A or PLB-S16E. Untransfected cells 
are shown for comparison. Data points are the mean from N = 3. Hill fits shown as lines. 
C) Vmax from the data in (B) was calculated by subtracting the untransfected ATPase 
activity from the transfected activity at pCa = 5.0. Mean ± SD, N = 3, unpaired t-test, p = 
0.11. D) Vmax measurements for microsomes transfected with equal amounts of wild 
type and D351A SERCA without PLB or in a 1:5 molar ratio with PLB-S16A or PLB-S16E. N 
= 72 for each treatment. 
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 not significant (figure 26C). However, these samples only expressed PLB at a 1:1 ratio 
with SERCA. We hypothesized that more PLB might be necessary to observe a full 
functional effect. We repeated ATPase measurements in microsomes expressing wt and 
D351A SERCA in a 1:5 ratio with PLB. Measurements at saturating calcium (pCa = 5.0) 
showed similar Vmax values for SERCA in the absence or presence of non-
phosphorylatable (S16A) PLB. This suggests that functional coupling is not modulated by 
PLB binding or unbinding. However, SERCA in the presence of phosphomimetic (S16E) 
PLB showed a marked increase in Vmax, indicating that a functional coupling mechanism 
may be present that is altered by phosphorylation of PLB (figure 26D). Specifically, this 
functional mechanism that alters Vmax is distinct from the physical dimerization 
observed. That is, dimerization by itself does not alter Vmax unless phosphorylation of 
PLB is engaged. 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
 
CHAPTER FIVE 
DISCUSSION 
Diverse experimental approaches have provided evidence for SERCA homo-
oligomerization (Vanderkooi, Ierokomas et al. 1977, Chamberlain, Berenski et al. 1983). 
Previous studies have provided various estimates of the stoichiometry of the SERCA 
oligomeric complex, with evidence supporting dimers (Negash, Chen et al. 1996, Yao, 
Chen et al. 2001, Mahaney, Albers et al. 2005, Chen, Yao et al. 2009), trimers (Mahaney, 
Thomas et al. 2008), or higher order oligomers (Voss, Birmachu et al. 1991, Mersol, 
Kutchai et al. 1995, Voss, Mahaney et al. 1995). The present results are consistent with a 
SERCA homo-dimer, as we observe a linear increase in donor fluorescence with the 
progressive photobleaching of acceptor (figure 18B). This linear relationship was 
preserved even at the highest levels of protein expression, suggesting that the dimer 
does not proceed to higher order oligomerization. The SR membrane in the heart 
contains abundant expression of SERCA. The junctional SR is estimated to contain more 
than 50% SERCA and the longitudinal SR is estimated to contain as much as 90% SERCA 
(Meissner 1975). Based on these estimates, we speculate that most of the SERCA in the 
heart would be in a dimeric state. 
It is interesting to note that the electrophoretic mobility of cross-linked SERCA 
band 2 (230 kDa) is slightly greater than 2-fold that of the monomeric band 1 (99 kDa) 
(figure 7B). Previous gel filtration experiments by Yamamoto et al. observed an apparent 
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dimer fraction with electrophoretic mobility larger than 2-fold that of the monomer 
(Yamamoto, Yantorno et al. 1984). This may indicate the presence of an accessory 
protein in mediating homo-dimerization, although we did not identify any such protein. 
We observed this phenomenon in both HEK cells (devoid of PLB) and rabbit LV 
cardiomyocytes (containing abundant PLB), indicating that any such protein would have 
to be present in both systems. Other work in our lab has shown that PLB is also captured 
in our cross-linked species (data not published); although this alone does not account 
for the 30 kDa shift.  
Multiple types of experiments have indicated the presence of a SERCA homo-
dimer in live cells. One problem that has eluded an answer thus far is the interface for 
SERCA protomer interaction. Incubation of cells with various SERCA antibodies did not 
produce alterations in dimer structure or affinity. However, the 6 custom antibodies 
used all targeted the P-domain while the commercial antibody epitope was unknown. 
This suggests the possibility that the P-domain is not the interface for dimerization; 
however, this cannot be completely ruled out as antibody binding to SERCA in these 
cells was not verified through immunohistochemistry. We also generated large 
fragments of the SERCA peptide in an attempt to compete the SERCA homo-dimer FRET. 
The short fragments localized to the cytoplasm, even when they contained parts of the 
TM domain. We did not detect competition by these fragments, although a specific 
short peptide may be capable of competing for the dimer interaction. If a precise 
determination of the dimer interface is made, FRET competition by a short peptide 
fragment could prove useful for verifying the interaction. This would be especially useful 
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to determine whether these peptides alter the functional effects that we observed in 
this study. 
Mass spectrometry could prove to be a useful tool for examining the site of 
interaction. Cross-linking with BPM is irreversible, so extraction from the gel should 
yield peptide fragment sizes that are altered. This technique may prove technically 
challenging if multiple cross-links are present and include multiple accessory proteins. 
We predict that another protein is present as the molecular weight of the cross-linked 
SERCA is shifted by more than two-fold; however, mass spectrometry could prove useful 
for identifying any such additional proteins. Our previous attempts to mutate four 
different cysteines on SERCA were not successful in abrogating the cross-link formed by 
BPM. It is possible that, while our data show a direct physical interaction between 
SERCA protomers, the observed cross-link is due to reactivity of a cysteine on a partner 
protein that forms a cross-link to a carbon on SERCA with the benzophenone group. 
Thus mass spectrometry has great potential to identify any accessory proteins as well as 
possibly identify the interface for SERCA dimerization. 
While some studies have suggested that SERCA dimerization is a regulated 
process, we did not see any evidence for this. Physical interaction between SERCA 
protomers does not appear to be modulated, indicating a constitutively present homo-
dimer. PLB was not required for homo-dimerization and SERCA conformational poise did 
not alter binding affinity or homo-dimer structure. HAX-1 was previously shown to 
regulate SERCA activity via PLB, however we did not detect a structural change in the 
SERCA homo-oligomer. Although we did note that HAX-1 increases both SERCA and PLB 
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expression, something that should be examined in more detail. Despite the large 
structural change to SERCA that we detected with the addition of TG or calcium shown 
here and previously (Hou, Hu et al. 2012, Pallikkuth, Blackwell et al. 2013), we did not 
detect a change in the oligomeric state of SERCA, indicating that oligomerization is not 
modulated be conformational poise. Inhibitors such as TG and melittin do not appear to 
regulate SERCA function through interactions between SERCA protomers as others have 
shown. It is interesting to note that the large structural changes to SERCA observed with 
both calcium and TG did not alter oligomeric FRET, suggesting that the acceptor and 
donor N-terminally labeled A-domains move in a coordinated fashion with binding of Ca 
or TG.  
In the present study we investigated the regulatory complex in detail using FRET 
from SERCA to PLB. Steady state acceptor-sensitized FRET measurements of 
fluorescently-labeled PLB and SERCA showed that FRET increased with protein 
concentration, similar to previous measurements (Kelly, Hou et al. 2008, Hou and Robia 
2010). Photobleaching revealed a linear relationship between the Cer-SERCA donor and 
YFP-PLB acceptor, indicative of a single PLB in the regulatory complex. However these 
data do not rule out the possibility of multiple Cer-SERCA donors in the complex. 
Fluorescence lifetime measurements enabled us to resolve multiple FRET 
subpopulations within a single cell. We observed that there are always donors that do 
not participate in FRET, even at the highest protein concentrations where binding 
interactions appear to approach saturation. One may consider several possible 
interpretations of this result. There may simply be a fraction of SERCA that is 
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inaccessible to PLB. We did not observe any mislocalization of SERCA fluorescence, 
which was 100% colocalized with PLB, so any such sequestration of SERCA would have 
to be in membrane microdomains that are below the resolution limit of fluorescence 
microscopy. However, it seems implausible that the proportion of inaccessible SERCA 
would decrease with increasing protein expression down to a minimum of almost 
exactly 50% of total SERCA (figure 24D). A second alternative hypothesis is that only 
SERCA molecules with the appropriate conformational poise can interact with PLB 
(Chen, Stokes et al. 2003). Again, it seems surprising that this proportion of pumps in 
the accessible state would titrate to 50%. Moreover, we have previously shown that 
calcium only modestly alters the PLB-SERCA binding affinity (Bidwell, Blackwell et al. 
2011), suggesting that PLB can bind to SERCA without regard to conformational poise. 
Therefore, we interpret the present data as indicative of a model in which the SERCA 
dimer interacts with PLB such that only one of the two donors in the complex may 
perform FRET with the acceptor on PLB. Several structural schemes could satisfy this; 
one simple arrangement is diagrammed in figure 27 where a dimer of SERCA protomers 
interacts with a single PLB. The leftmost donor GFP, which is bound to the left/front 
SERCA protomer (dotted outline), is >100 Å away from the mCherry (“R”), too far to 
participate in FRET. The donor bound to the SERCA protomer on the right is 54 Å from 
the mCherry, supporting robust FRET. Thus, no matter how much increasing protein 
expression drives the equilibrium toward the bound complex, the population of donors 
participating in FRET can never exceed 50% of the total. Thus, the maximal FRET 
measured by steady-state methods (figure 20B) 
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Figure 27. A model of the SERCA-SERCA-PLB regulatory complex in which the GFP on 
one of the SERCA protomers (dotted outline) is too distant to participate in FRET with 
PLB. 
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 (Kelly, Hou et al. 2008, Hou and Robia 2010) is half of that quantified from the short 
lifetime component (τS) of a FRET donor fluorescence decay (figure 24C). 
Previous estimates of the stoichiometry of the regulatory complex have 
suggested that PLB binds to SERCA in a 1:1 relationship (Mueller, Karim et al. 2004). 
However, studies have reported expression of SERCA and PLB to be anywhere from 1:5 
to 4:1, indicating that PLB may not actually regulate SERCA in a 1:1 molar ratio in vivo 
(Louis, Turnquist et al. 1987, Negash, Chen et al. 1996, Ceholski, Trieber et al. 2012). This 
is supported by previous results using transgenic mice overexpressing PLB in the heart, 
indicating that the native functional stoichiometry of the regulatory complex is less than 
one PLB per SERCA (Kadambi, Ponniah et al. 1996). Furthermore, it has been noted that 
a large quantity of PLB exists as the highly stable pentamer reserve pool, leaving less 
monomers available for inhibition of the calcium ATPase. Our data may explain how full 
inhibition of SERCA by PLB is observed even though estimates of PLB indicate that 
expression might not be high enough for 1:1 binding.  
While some studies have suggested that SERCA dimerization is a regulated by 
PLB phosphorylation (Negash, Chen et al. 1996, Mahaney, Albers et al. 2005), we did not 
observe a change in either the structure or the binding affinity of the homo-dimer in 
response to PLB binding or PLB phosphorylation or Ca binding (figure 13). It is possible 
that SERCA is always physically coupled, but PLB phosphorylation engages functional 
coupling of the protomers. This hypothesis is compatible with reports that indicate that 
phosphorylated PLB increases SERCA Vmax (Lu and Kirchberger 1994, Antipenko, 
Spielman et al. 1997, Reddy, Cornea et al. 2003), (though other groups did not observe a 
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Vmax change (Movsesian, Colyer et al. 1990, Morris, Cheng et al. 1991, Movsesian 1992, 
Reddy, Jones et al. 1995, Odermatt, Kurzydlowski et al. 1996)). Importantly, PLB-
dependent functional coupling implies that phosphorylated PLB stays bound to SERCA 
throughout the calcium transport cycle, a concept that is supported by many studies (Li, 
Bigelow et al. 2004, Mueller, Karim et al. 2004, Bidwell, Blackwell et al. 2011) but not all 
(Kimura, Kurzydlowski et al. 1997, Jones, Cornea et al. 2002). Our lab has previously 
reported spectroscopic evidence for a particularly compact and ordered conformation 
of SERCA when bound to phosphorylated PLB and calcium (Pallikkuth, Blackwell et al. 
2013). This conformation may be the structural signature of functionally coupled SERCA 
dimers. 
Future experiments could take advantage of the other two labeled sites (509 and 
C-term) to more accurately measure FRET, as this current study only examined the N-
term label in detail. These other sites may prove useful in triangulating the relative 
positions of the Cer-SERCA N-term label relative to the YFP-labeled SERCA. Furthermore, 
our model suggests that one SERCA in the homo-dimer is not capable of FRET with PLB 
due to distance constraints. Fluorescence lifetime measurements from these other sites 
may reveal two populations that are both capable of FRET with the YFP-PLB, thus giving 
a better estimate of the position of the cytosolic domain of PLB relative to the SERCA 
homo-dimer. 
Previous studies suggested that SERCA homo-oligomerization is functionally 
regulated by phosphorylated PLB. Several key functional studies suggested that SERCA 
dimer activity is greater than the sum of its parts (Chamberlain, Berenski et al. 1983, 
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Chen, Yao et al. 2009). However, detergent-solubilized SERCA1a, which is greater than 
80% monomer, is still catalytically active (Vilsen and Andersen 1987), suggesting that 
dimerization is not obligatory for function. However, our own cross-linking studies 
showed that some dimers persist even under conditions of 1% DPC. Our data show two 
important functional changes with PLB. First, the cooperativity of calcium-dependent 
ATPase activity increases in cardiac microsomal preparations compared to skeletal 
preparations, suggesting that this effect is modulated by interaction with PLB. Gorski et 
al. also observed an increase in cooperativity with the addition of PLB, although they did 
not attribute this increased cooperativity to functional coupling of SERCA protomers 
(Gorski, Glaves et al. 2013). It is not yet clear whether this cooperativity is due to 
physical association or activation of PLB. Second, we noted that phosphorylated PLB 
alters Vmax, in agreement with a secondary role for regulation by phosphorylation (the 
first being calcium sensitivity). Examination of detergent-solubilized SERCA suggests that 
the composition of the lipid environment and the detergents used are crucial 
determinants of SERCA activity (Vilsen and Andersen 1987, Gustavsson, Traaseth et al. 
2011). This may help explain the inconsistency in past measurements of Vmax and 
cooperativity in the literature. In fact, Gustavsson et al. showed that certain lipid 
compositions had far more potent effects on both calcium sensitivity and Vmax than did 
PLB (Gustavsson, Traaseth et al. 2011), indicating that the experimental conditions may 
play a large role in the results obtained. 
Further work in the field should examine the calcium ATPase activity to 
determine how PLB increases cooperativity. SERCA calcium uptake in the absence of PLB 
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has a Hill coefficient slightly less than 2 due to enhancement of the calcium binding 
affinity at site II following calcium binding to site I. However, we detect increased 
cooperativity in cardiac preparations that appears to be due to PLB. Further work should 
examine how PLB modulates increased calcium sensitivity as this does not appear to be 
dependent on phosphorylation, which is distinct from the Vmax alterations observed with 
phosphorylation. Additional experiments should examine ATPase activity over the full 
range of calcium to determine the effects of S16E on Vmax. Titration of PLB may provide 
an interesting tool for determining the range of Vmax changes with phosphorylation. 
Measurements should also be made to compare the present results with the Vmax 
effects in microsomes expressing 100% wt SERCA or 100% D351A SERCA. 
As mentioned in the introduction, multiple studies showed that phosphorylation 
of PLB was unable to fully correct the decrease in SERCA activity observed in samples 
obtained from HF. Our data may provide an explanation for decreased SERCA activity in 
HF and the inability of phosphorylation of PLB to overcome reduced activity. Previous 
studies have shown that SERCA activity is decreased more than expected for the change 
in expression evidenced during HF (Schwinger, Bohm et al. 1995, Zarain-Herzberg, Afzal 
et al. 1996) or in vivo (Chamberlain, Berenski et al. 1983). It is tempting to speculate that 
decreases in SERCA activity observed during HF may be a result of functional coupling. If 
a percentage of the SERCA protein becomes post-translationally modified such that it 
cannot functionally couple with other SERCA protomers, then it would not be able to 
achieve a similar rate of calcium transport. Combined with reduced levels of PLB 
phosphorylation observed in HF, SERCA activity would be reduced even further as 
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evidenced in figure 26D. This may also explain why a recent clinical trial to overexpress 
SERCA was not successful, as the endogenous SERCA in HF acts in a dominant negative 
fashion to prevent exogenously-expressed SERCA from reaching full rates of calcium 
transport. In fact, in vivo studies have shown that certain post-translational 
modifications reduce SERCA activity (Lancel, Qin et al. 2010). I hypothesize that these 
pumps may act in a dominant negative fashion; that is, they physically couple with other 
SERCA protomers but do not contribute enzymatically. 
Conclusion 
The functional implication of a single PLB regulating a pair of SERCA is unclear, 
however one may speculate that this stoichiometry would make PLB relatively more 
potent in modulating transport activity. In particular, estimates of the in vivo expression 
ratio of PLB to SERCA range from 1:5 to 4:1, and a substantial portion (~80%) of the PLB 
is pentameric and therefore inaccessible to SERCA (Cornea, Jones et al. 1997). 
Regulation of two SERCA pumps by a single PLB would explain this apparent regulatory 
protein expression mismatch. The stoichiometry may also account for the greater 
cooperativity of Ca-ATPase activity in cardiac muscle compared to skeletal muscle 
lacking PLB. If PLB engages functional coupling of the two SERCA molecules, the number 
of Ca-binding sites per transport unit is effectively increased. Indeed, some 
superinhibitory PLB mutants can deliver Hill coefficients that exceed 2 (Trieber, Afara et 
al. 2009). Finally, the present results have implications for human disease, particularly 
heart failure, in which SERCA activity is decreased as a result of changes in SERCA:PLB 
ratios, SERCA expression levels (Hasenfuss, Reinecke et al. 1994) or changes in SERCA 
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specific activity (Schwinger, Bohm et al. 1995, Schmidt, Hajjar et al. 1999). The present 
results suggest that deviation from optimal protein expression level or damage to a 
fraction of the SERCA population may yield a larger than expected functional deficit as a 
consequence of altered conformational coupling.  
Our data support a quaternary regulatory complex containing a single PLB bound 
to a pair of SERCA protomers. We observe SERCA2a dimers in the absence/presence of 
PLB and the dimers do not require PLB phosphorylation in order to assemble. Moreover, 
cross-linking experiments suggest that SERCA2a readily forms dimers in the native 
environment of the sarcoplasmic reticulum membrane of the cardiac muscle cell. SERCA 
dimers are functionally coupled by PLB, which increases cooperativity of calcium binding 
and alters Vmax. 
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